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IDENTIFICATION AND MOLECULAR ANALYSIS OF DNA IN
EXOSOMES

Jena Tavormina, Sc.B.
Advisory Professor: Raghu Kalluri, M.D., Ph.D.

Exosomes are heterogeneous nanoparticles 50-150nm in diameter. Exosomes
contain many functional cargo components, such as protein, DNA, and RNA. While
protein and RNA exosome content has been extensively studied, very little work has
been done to characterize exosomal DNA. Here, we demonstrate that exosomal DNA
is heterogeneous and its packaging into exosomes is dependent on the cell of origin.
Furthermore, through a rigorous assessment of various isolation methods, we identify
Size Exclusion Chromatography (SEC) as the best method for the isolation of
exosomal DNA for downstream applications. Additionally, we evaluate the methylation
status of exosomal DNA and demonstrate that exosomal DNA is both methylated and
fully recapitulates the methylation patterns observed in the cells of origin. We also
propose a potential mechanism for DNA packaging into exosomes by disruption of the
nuclear membrane. Finally, we investigated the ability of exosomes to induce
paracrine DNA damage responses (DDR) in treatment-naïve cells. We explore the
specificity of exosome-induced DDR to exosomes released by damaged cancer cells,
and provide a potential molecular mechanism of action via the shuttling of activated
DDR pathway proteins.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE

1

Biogenesis, Characteristics, and Functions of Exosomes
Early Exosome Discovery and Overview
The initial identification of the class of nanoparticles now known as exosomes
occurred almost 40 years ago. While there were earlier accounts of small vesicles
secreted from certain cell types, such as chondrocytes1,2 and platelets3, the term
‘exosome’ was not used until Trams et al. published the first account of membrane
particles isolated from biological fluid in 19814. Their landmark paper was the first to
state that exosomes could come from a wide variety of cell types, including both
normal and neoplastic, as part of a general biological process that could preferentially
sort cargo for packaging and transfer it to recipient cells4. Thus, this was the first
suggestion of the potential of exosomes for intercellular signaling and, further, for their
use as therapeutic delivery vehicles.
Two years later, in 1983, two seminal papers were published that served as the
true foundation for the field of exosome research. Both investigated transferrin
receptors in reticulocytes, and showed that the receptors were released from cells via
vesicles5,6. Additionally the first of those papers, published by Harding and Stahl,
showed for the first time that multivesicular endosomes, or MVEs, contained small
vesicles that were then ejected into the extracellular environment upon fusion with the
plasma membrane, becoming the first study to demonstrate the general mechanism
of exosome release5. At the time, late endosomes were only thought to be predegradative compartments, with their contents designated specifically for lysosomal
degradation. Therefore, the discovery that certain late endosomes could fuse with the
cellular membrane and release contents was quite controversial, since most believed
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that any vesicles retrieved by ultracentrifugation were membrane components of dying
cells in culture. More recently, electron microscopy has been used to demonstrate
membrane fusion events between late endosomes and the plasma membranes of
living cells7,8, validating the initial findings. The name exosome was officially linked
specifically to 40-100nm nanoparticles released via MVE fusion in Rose Johnstone’s
1987 paper, which further characterized the release pathway as being distinct from
cellular stress responses9.
In the decades since exosomes were first identified the field has rapidly
expanded, generating a massive amount of data regarding the characterization,
functions, and applications of exosomes. Exosomes are now known to be released
from virtually every cell type, including but not limited to immune cells7,8, neurons10,11,
stem cells12,13, and cancer cells14–16. Exosomes have also been found to be released
by prokaryotes and eukaryotes in addition to mammalian cells17,18. Importantly,
especially for clinical applications, exosomes have been isolated from a wide variety
of biological fluids, such as serum19,20, urine21, breast milk22, amniotic fluid23, saliva24,
semen25, and cerebrospinal fluid26. The therapeutic applications of these bodily fluidderived exosomes are still being explored, but the potential for diagnostic and
therapeutic implementations of exosomes for many different diseases is enormous.
Beginning with the groundbreaking study published by Raposo et al. in 1996,
in which it was shown that exosomes could induce adaptive immune responses by
acting as antigen presenting vesicles via MHC class II complexes present on their
membranes8, exosomes have been demonstrated to have a wide variety of functions.
In addition to their roles in immunity, exosomes have also been implicated in cellular
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signaling and biological processes, under both normal physiological and pathological
conditions. It is these functional characteristics of exosomes that drive much of the
research in the field today, on a breadth of topics including stem cell maintenance12,
tissue repair27, neuronal synaptic responses28, or most relevant for this work,
tumorigenesis29–32, among others. In addition to cancer, exosomes have been linked
to a variety of other diseases, including HIV33, Alzheimer’s34, and Parkinson’s
disease35, and are under investigation for both diagnostic and therapeutic
applications.
As exosome research has become more widespread, many advances have
been made regarding their isolation and identification. There are now many different
exosome isolation methods, which differ in efficacy depending on the desired
downstream application. These methods will be discussed in greater detail
subsequently. In parallel with the development of improved exosome isolation
techniques, exosome-specific markers have also been identified since exosomes can
now be obtained with greater purity. The most commonly used exosome markers are
known as tetraspanins, transmembrane proteins with a variety of functions including
cell adhesion, motility, and membrane fusion36. The first tetraspanin to be identified
as specifically associated with exosomes was CD9, which was discovered by Théry
et al. in the exosome pellets of dendritic cells in 19997. Since then, CD63 and CD81
have most often been cited as the most classical markers of exosomes37,38, however
there has been evidence of other classes of microvesicles containing some of the
same tetraspanins, likely due to the wide distribution of tetraspanin expression
throughout the plasma membrane39. Therefore, tetraspanins are necessary but no
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longer sufficient to precisely identify exosomes, and other markers have been
identified to supplement tetraspanin expression, such as flotillin, TSG101, integrins,
lactadherin, and RAB5/RAB740,41. Additionally, exosomes are characterized by the
absence of certain markers, such as calnexin, GM130, and cytochrome C, to indicate
they are not apoptotic bodies42.
Finally, exosomes have been shown to have heterogenous and diverse cargo
components that generally reflect the cell of origin and have a variety of functions and
potential uses. While these will later be described in more detail, what follows is a brief
description of some of the major categories of exosome contents. Perhaps the most
commonly studied class of exosome cargo is protein. Many proteins have been
identified either on the membranes of exosomes, such as the aforementioned
tetraspanins36, or encapsulated within them40,43. Many species of RNAs have also
been demonstrated to be carried by exosomes, including mRNA, miRNA, tRNA, and
rRNA, YRNA, and Vault RNA30,43–45. Another important nucleic acid, DNA, is also
present in exosomes and was first identified (in double-stranded form) as an exosomal
cargo component by the Kalluri laboratory in 201446. That finding was swiftly
corroborated by other groups, and ssDNA and mtDNA have also been shown in
exosomes11,47–49. These studies set the early foundation for much of the work done in
this project. Other exosomal cargo components include lipids, cytoskeleton
components, and enzymes40,43,44,50. A growing area of interest of therapeutic
relevance is the loading of exosomes with specific cargo for delivery to target cells.
One example of this was work done in our lab that utilized exosomes to deliver siRNA
targeting oncogenic KRASG12D to pancreatic ductal adenocarcinoma (PDAC) tumors
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in mice, resulting in extensive tumor burden reduction and suppression of KRASG12D
expression51. This work is now in clinical trial, and many other studies involving
exosomes as therapy delivery vehicles are ongoing.

Figure 1. Exosome Components.
Exosomes contain heterogenous cargo components, which can include RNA, DNA
and both intraluminal and membrane proteins.
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Mechanism of Exosome Biogenesis
Since Harding and Stahl first observed exosome release via MVE fusion
with the cellular membrane5, much has been discovered regarding the biological
processes of exosome biogenesis and release. Generally speaking, the pathway
involves multivesicular bodies containing intraluminal vesicles, or exosomes, forming
and subsequently fusing with the plasma membrane of the cell of origin, releasing the
exosomes into the intercellular space52. Exosome biogenesis is comprised of three
major stages, the formation of endocytic vesicles, multi-vesicular body (MVB)
generation via the inward budding of the endosomal membrane to form intraluminal
vesicles (ILVs), and the fusion of MVBs with the parent cell’s plasma membrane with
resultant exosome release50. While many of the proteins and molecules involved in
the biogenesis and release of exosomes have been identified, due to technical
limitations there is still a lack of clarity regarding the roles of certain molecules at each
step. There is also conflicting information regarding which molecules are important for
exosome biogenesis, possibly due to factors such as choice of isolation method or
cell type-specific dependencies. Additionally, since much of the exosome biogenesis
pathway has only recently been defined, there are likely still components that have
not yet been described.
Exosome formation begins with the maturation of early endosomes into late
endosomes. During the maturation process, the endosomal membrane invaginates
and forms ILVs within the lumen of the endosome, forming an MVB53. The ESCRT
complex machinery, a collection of about 30 proteins assembled into 4 complexes50,
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is integral to this process. The ESCRT-0 complex recognizes and traps ubiquitinated
transmembrane proteins in the endosomal membrane, while the ESCRT I & II
complexes are involved in membrane deformation and the formation of buds with
sorted cargo54. The ESCRT III complex is responsible for separating the newly formed
vesicles from the membrane54. Several distinct ESCRT proteins have been clearly
demonstrated to be important for the successful secretion of exosomes, namely Hrs,
TSG101, and STAM155. Additionally, the related protein ALIX has been implicated in
the loading of cargo and selection of MVBs for maturation and secretion55.
The ESCRT proteins (ESCRTs) may not be completely necessary for exosome
release, as silencing key subunits of all 4 ESCRT complexes does not entirely
eliminate the formation of ILVs56. Tetraspanins, specifically CD9, CD82, Tspan8, and
CD63, have been implicated in ESCRT-independent exosome release57–59, as has the
lysosome/late endosome associated protein SIMPLE60. Lipids have also been shown
to work together with these proteins as important actors in vesicular formation and
transport processes such as membrane curvature, invagination, fission and fusion61.
The role of lipids in exosome formation is supported by studies targeting lipid
modifying enzymes, such as the inhibition of sphingomyelinase 2 (nSMase2) which
has been shown to reduce exosome release, potentially due to the subsequent lack
of formation of ceramide microdomains that cause membrane budding to occur62.
Other lipid modifying enzymes, such as phospholipase D2 (PLD2) and diacylglycerol
kinase α (DGKα), have also been identified as having a role in regulating ILV formation
in exosome biogenesis63,64. The maturation of endosomes into MVBs is likely to rely
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on these different components either separately or combined based on the conditions
present in a given cell type and microenvironment65.
Once an endosome has matured into an MVB, it will either be targeted to
lysosomes, which results in the degradation of its contents, or transported to the
plasma membrane of the cell for fusion and release. How MVBs are designated for
either degradation or secretion remains a mystery, but some groups have identified a
few potential markers, such as post-translational modifications66. If an MVB avoids
degradation, it must physically move through the cytosol to the plasma membrane.
This process is mediated by MVB interactions with cytoskeletal components of the
cell, namely actin and microtubules67,68. Additionally, the Rab GTPase family is known
to be involved in several steps of the membrane trafficking process, including budding,
transport along actin and tubulin, and membrane fusion. Several of these Rab
GTPases have been implicated specifically in the exosome biogenesis pathway, such
as Rab11, Rab35, and Rab27a/b, which have been the most characterized69,70. Other
small GTPases may also be involved in exosome release, such as the RhoGTPase
citron kinase71. It is worth mentioning that while all of these molecules have been
implicated in exosome release, some studies have shown that their involvement may
be dependent on cell type72–74, meaning there is likely at least some degree of
functional redundancy in the MVB trafficking pathway. Additionally, the high likelihood
that there are as-yet unidentified additional molecules involved in the process
demonstrates the need for further clarity regarding the MVB-to-membrane transport
mechanisms.
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Once the MVBs arrive at the plasma membrane, several steps must occur to
achieve proper membrane fusion and exosome release. Multiple proteins have been
identified as fusion facilitators, in addition to providing docking specificity. Chief among
these are the soluble N-ethylmaleimide-sensitive factor attachment protein receptors
(SNAREs), as well as tethering factors, Rabs, and select other Ras GTPases75.
SNAREs have been shown to enable vesicles to fuse with specific target membranes,
either the plasma membrane of the cell or the membrane of another organelle76. The
SNARE family is split into two classes, R-SNAREs and Q-SNAREs, and fusion usually
requires one R-SNARE and three Q-SNAREs to form a complex which then enables
the MVB to dock at the plasma membrane75. SNAREs act together with Rab GTPases
and tethering factors to complete vesicle targeting and fusion with high efficiency77. It
is thought that Rab GTPases present on the surface of vesicles recruit the cytosolic
tethers to their membranes, which work in concert with tethers and SNARE complexes
on the target membrane to achieve fusion75. The precise mechanisms of this process
remain an active field of study.
Exosome release has been shown to be at least somewhat dependent on the
cellular microenvironment and relies on several aspects of cellular homeostasis. It has
been reported that cells under stress release more exosomes in a variety of contexts,
though the exact mechanisms are not always clear. For example, dying or senescent
cells were shown to secrete exosomes at a higher rate when compared with healthy
cells78,79. Additionally, cells subjected to DNA damaging agents and hypoxia were also
observed to release more exosomes80,81. While the exact purpose(s) of increased
exosome release in the context of stress remain unclear, it has been proposed that
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this could be a mechanism of releasing waste products detrimental to the cells or as
a means of sending a stress signal to neighboring cells as a form of intercellular
communication82.
Exosome Cargo
The functions of exosomes are all mediated by the biological components
contained either within or on exosomes. Exosomes have been shown to contain
heterogeneous and diverse cargo, which is largely dependent on the cell type of origin
as well as the microenvironmental conditions at the time of release. The mechanisms
of exosome packaging and cargo sorting remain unclear, but some progress has been
made in identifying mediators that determine what is loaded into exosomes during
biogenesis83,84. More substantial work has been done on identifying and
characterizing the molecules within exosomes, which include lipids, proteins, and
nucleic acids such as RNA and DNA40.
Lipids have not only been identified as exosome cargo, but also form the
exosomal membrane. The outer membrane of exosomes consists of a lipid bilayer,
similar to the plasma membrane of cells44. Compared with cells, exosome membranes
have been shown to be enriched in cholesterol, sphingomyelin, gangliosides, and
desaturated lipids, while they have less phosphatidylcholine and diacylglycerol85,86.
Exosomes have demonstrated an increased amount of phosphatidylserine on the
outer leaflet of their membranes, which has been proposed to aid their uptake by
recipient cells87. The increased rigidity of exosome membranes in comparison with
cell membranes, due to their high levels of sphingomyelin, cholesterol, and
desaturated lipids, has been correlated with their resistance to degradation and

11

stability, a key feature of exosomes as carriers of protected cargo88. Exosomes also
contain lipid metabolism enzymes, such as phospholipases A2 and D89, as well as
enzymes necessary for lipogenesis, including fatty acid synthase, palmitate and
stearate90,91. Finally, exosomes can also transport bioactive lipids to recipient cells,
such as arachidonic acid, prostaglandin E2, ceramide, and phosphatidic acid86,89.
The protein content of exosomes is quite diverse and is perhaps the most wellstudied exosomal cargo component. Exosome protein can vary widely depending on
cell type and biological context. There are two major categories of exosomal proteins,
those present on the membrane and those encapsulated within the lumen. Proteins
present on exosome membranes include major histocompatibility complex class II
(MHC class II) and tetraspanins (most commonly CD9, CD81, and CD63)40,92,93.
Exosomes also contain several proteins required for MVB biogenesis and release,
including the ESCRT proteins, Alix, TSG101, integrins, and chaperones such as
Hcs70 and Hsp9094. Since these proteins are involved in the general process of
exosome formation, they are often used as exosome-specific markers to indicate
vesicle purity after isolation. The protein content of exosomes, which can include
receptors, transcription factors, and enzymes, is often functional and can have marked
effects on recipient cells after uptake44. For example, glioblastoma cells could
successfully transport the oncogenic variant of epidermal growth factor (EGFRvIII) via
exosomes to activate the MAPK/Akt proliferation cascade in neighboring glioma
cells95. Overall, exosomal proteins are important mediators of intercellular signaling
processes.
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Almost every known species of RNA has been found within exosomes. As
expected, mRNA and miRNA were the first to be characterized14,96, but subsequent
studies have demonstrated the presence of rRNA, tRNA, siRNA, snoRNA, scRNA,
snRNA, lncRNA, and piRNA97,98. RNA species found in exosomes are usually smaller
in size than those found in cellular fractions, which is logical due to the small size of
nanoparticles98. The concentration of RNA in exosomes has been found to vary based
on the cell of origin, for instance several types of cancer cell exosomes have been
shown to contain significantly more RNA than normal cells49. Of note, while exosomal
RNA does to a large degree reflect the RNA profile of the cell of origin, some RNAs
have been observed to be enriched in exosomes14,96. Due to the enrichment of certain
RNA species in exosomes, there have been some investigations into potential
selective exosomal RNA packaging mechanisms99–101. Several studies have
implicated exosomes in the transfer of functional RNA to recipient cells. Recipient cell
translation assays have shown that mRNAs delivered by exosomes can be
successfully translated14,96,102. Additionally, microRNAs carried by exosomes could be
involved in the regulation of mRNA translation in recipient cells103,104. Finally,
advances in therapeutic applications of exosomes have led to the development of
exosomes loaded with specific RNA species for targeted treatment. In a major study,
Kamerkar et al. generated “iExosomes,” which contained siRNA specific to the
oncogenic KRAS variant KRASG12D. Treatment with the engineered iExosomes
suppressed tumors in pancreatic cancer mouse models and demonstrated a specific,
targeted approach for effective cancer therapy51. These observations demonstrate
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that exosomal RNA has functional consequences in recipient cells, and that it could
potentially be utilized as targeted therapy for previously difficult to treat diseases.
Easily the least characterized of the major exosomal cargo components, DNA
is also possibly the molecule with the most diagnostic and therapeutic potential.
Guescini et al. first reported the presence of mitochondrial DNA species within
exosomes in 201011, followed a year later by Balaj et al.’s discovery of single stranded
DNA in human and mouse glioblastoma exosomes49. Our laboratory was the first to
identify double-stranded DNA species in exosomes using PDAC patient serum
samples as well as immortalized cell lines46. Results from this study also determined
that when pooled, the exosomal DNA was able to be sequenced and spanned the
entire genome, and it also reflected the mutational status of the patient tumor or cells
of origin46. This study was the first to implicate the diagnostic potential of exosomes
isolated from patient body fluids for DNA-based mutational characterization,
diagnostics, and treatment monitoring, but a handful of others have since corroborated
those findings47,105–107. Since the membranes of exosomes prevent their contents from
degrading, exosomal DNA is protected from endogenous DNase activity that affects
other extracellular biomarkers such as circulating cell-free DNA, for example.
Evidence supporting this notion is seen in the relatively large fragment sizes of DNA
that are able to be isolated from exosomes, and their ability to be reliably sequenced46.
Accordingly, other groups showed reliable detection of BRAF and EGFR mutations in
melanoma-derived exosomes47.
There are still many mysteries surrounding exosomal DNA that remain to be
resolved. The relative scarcity of exosome DNA-related studies has contributed to the
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slow accumulation of information regarding the origin, packaging, and function of
exosomal DNA. A study by Takahashi et al. proposed that exosomal DNA may serve
as a mechanism of cellular homeostasis by removing ectopic DNA fragments from the
cytoplasm and preventing the activation of the cytosolic DNA-sensing stimulator of
interferon genes (STING) pathway108. Work from Kitai et al. also showed that
topotecan treatment significantly increased exosomal DNA production and led to
dendritic cell activation through the STING pathway in breast cancer cells109. Another
group proposed an entirely different role for exosome DNA, demonstrating that it could
be delivered to recipient cells, localized to the nucleus, and was potentially
transcribed110,111. Indeed, horizontal transfer of DNA via exosomes has been shown
in model organisms112, and altered phenotypes in recipient cells have been attributed
to the delivery of exosomal DNA48,113. These studies demonstrate that while some
progress has been made in terms of the characterization of exosome DNA, much
remains to be discovered. The limited amount of information available regarding
exosomal DNA, especially in comparison with the other exosome cargo components,
reveals a fundamentally broad lack of understanding in the field.
Biological Functions of Exosomes
Exosomes are diverse, heterogeneous nanoparticles which have been
implicated in a variety of biological processes. The function and cargo of exosomes
depends on the status and type of the cell of origin, as they have been shown to be
released from virtually all cell types during both normal physiological conditions and
at times of stress. Initially, exosomes were thought to be purely waste removal
vehicles with no additional biological activity or relevance40. However in the years

15

since the first exosomes were isolated, they have been demonstrated to have
important roles in a wide variety of biological applications, serving as carriers of
intercellular signals via their diverse cargo. Exosomes can successfully transfer
proteins, enzymes, lipids, RNA, and even DNA to recipient cells both locally and
systemically, and therefore are involved in many physiological and pathological
processes65.
The first indication that exosomes could perform distinct biological functions
came from the seminal study by Raposo et al., which showed that B cell exosomes
could present MHC class II peptide complexes to T cells and induce an immune
response8. Subsequently, it has been discovered that exosomes have a variety of
immunomodulatory functions. Dendritic cells, for example, were also found to release
T-cell activating exosomes that were so effective they could reduce tumor burdens in
mice7,114. Surface bound macrophage-derived exosomes have also been shown to
have the ability to present antigens to T cells115. Additionally, there is even evidence
that exosomes released by immune cells can mediate antigen presentation, inducing
immune responses on their own116. Conversely, regulatory immune cells (Tregs) also
release exosomes that are able to decrease immunogenicity by preventing CD4+ T
cells

from

activation

and

inducing

tolerogenic

dendritic

cells117,118.

The

immunosuppressive abilities of Treg exosomes have been attributed to a variety of
transported cargo, including miRNAs, chemokines, and interleukins117. Exosomes
from immunosuppressive mesenchymal stem cells (MSCs) have been observed to
inhibit macrophage responsiveness by causing impaired recognition of Toll-Like
Receptors (TLRs)119, and have also been shown to promote Treg differentiation120.
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Furthermore, exosomes have been observed to facilitate cytokine delivery at immune
synapses between T cells and antigen presenting cells (APCs), serving to propagate
immunomodulatory signals between cell types121. Exosomes have many established
roles in immune response signaling, with more to be discovered. Current research
seeks to further clarify the roles of exosomes in immune signaling, as well as explore
their potential utility for immunotherapy applications.
In addition to their abilities to activate or suppress immune cells, exosomes
have become known as potent mediators of inflammation. Circulating exosomes
demonstrate the ability to induce the release of several pro-inflammatory cytokines,
such as interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα) and chemokine C-C
motif ligand 2 (CCL2)122. Exosomes have also been implicated in the pro-inflammatory
processes of several diseases, including cancer123, inflammatory bowel disease124,
diabetes125,

obesity126,

and

rheumatoid

arthritis127.

The

mediation

of

neuroinflammation in several neurodegenerative diseases, including Alzheimer’s and
Parkinson’s, has also been linked to exosomes containing factors such as αsynuclein, amyloid β, and prions128. Work investigating the exosomes released during
the pathogenesis of chronic inflammatory states includes attempts to identify novel
exosome-associated biomarkers that could be used for diagnosis and treatment
monitoring of inflammation-mediated diseases129.
Another biological function linked to exosomes is apoptosis, an important
process for both healthy and diseased cells involving programmed cell death. It has
been well established that dying cells release large microvesicles, called apoptotic
bodies, that can be up to several microns in diameter130. More recently, the smaller
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microvesicle population of exosomes has also been associated with apoptosis-related
signaling and functions. Stromal cell-derived exosomes, for instance, have been
observed to release anti-apoptotic signals to support the survival of neighboring tumor
cells131. Additionally, cardiac progenitor cells (CPCs) can release exosomes that
protect cardiomyocytes from oxidative stress by preventing ischemia- and
reperfusion-induced

apoptosis132.

Placental

cells

of

the

syncytiotrophoblast

constitutively release exosomes into the bloodstream that inhibit the function of the
maternal immune system and promote fetal survival through their high levels of proapoptotic molecules such as Fas ligand (FasL), TRAIL, and PD-L1133. Cancer cellderived exosomes have also exhibited immunosuppressive and pro-tumorigenic
capabilities through the induction of T cell apoptosis via delivery of FasL134. The ability
of exosomes to mediate both pro- and anti-apoptotic cell fates demonstrates their
importance as a mechanism of maintaining cellular homeostasis, the disruption of
which can lead to pathogenic consequences.
In addition to apoptosis, exosomes are also involved in signaling pathways
related to cell proliferation. Exosomes have been shown to induce proliferation in a
variety of cell types, including T cells8, stem cells135, and especially cancer
cells95,136,137. The capability of exosomes to help promote and sustain proliferative
signaling is the subject of intensive study in the cancer biology field. Modulation of
exosome proliferative signaling, whether through the inhibition of exosome release or
the manipulation of their cargo, is a potential therapeutic avenue for the inhibition of
tumorigenesis138. Additionally, some groups have investigated the potential utility of
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exosome proliferative signaling for stem cell regeneration139,140. Thus, cell proliferation
signaling is one of the most therapeutically relevant biological functions of exosomes.
Another similar function of exosomes is the mediation of angiogenesis, or the
formation of new capillaries from existing blood vessels141. T lymphocytes, which
closely interact with vascular endothelial cells during circulation and trans-endothelial
migration, have demonstrated the ability to alter VEGF signaling and tube formation
through

exosomes142.

Trophoblast

cells

generate

extracellular

matrix

metalloproteinase inducer (EMMPRIN)-containing exosomes that have been
implicated in placental angiogenesis and remodeling143,144. Additionally, exosomes
isolated from mesenchymal stem cells (MSCs) have been shown to enhance
angiogenesis during skin repair after severe burns145. The bulk of the research done
on exosome-mediated angiogenesis, however, has occurred in cancer-related
contexts, as one of the hallmarks of cancer is the aberrant formation of new
vasculature to provide nutrients to growing tumors146,147. For example, it has been
shown that cancer cell derived exosomes taken up by endothelial cells promote
angiogenesis via induction of the pro-angiogenic secretome32,148. Additionally,
melanoma cell exosomes have been found to promote metastasis by recruiting
circulating melanoma cells to the endothelium, while simultaneously releasing proangiogenic and extracellular matrix remodeling factors to encourage tumor
formation149. Tumor exosomes were also shown to transfer activated EGFR to
endothelial cells, leading to the induction of VEGF expression and subsequent
stimulation of angiogenesis15. Exosomes derived from cancer cells have also
demonstrated the ability to impair the structural integrity of endothelial cells by

19

downregulating tight junction proteins such as ZO-1, enhancing vascular permeability
and thereby facilitating metastasis150. Since angiogenesis is so closely associated with
various pro-tumorigenic and metastatic mechanisms, such as proliferation, migration,
and extravasation151, the influence of exosome-mediated signaling on angiogenic
processes are being investigated as potential avenues for therapeutic intervention
against metastatic dissemination and tumor formation.
There is substantial evidence for the importance of exosomes in a wide variety
of biological functions. The roles of exosomes described here, while extensive, are by
no means completely comprehensive. Exosomes are beginning to be implicated in
even more areas, such as DNA damage response152 and metabolism153. These
diverse capabilities underscore the importance of exosomes in virtually all biological
signaling pathways and highlight the vast potential for the development of exosomebased therapeutics.
Exosomes in Cancer
Exosomes have been implicated in several processes associated with tumor
progression and metastasis, and cancer-related research is a major field of exosome
work, due to the enormous potential for exosomes in diagnostics and
therapeutics154,155. Since exosomes are so readily available in easily accessible
biofluids such as serum and urine, they have been investigated for their utility for liquid
biopsy23,156. Exosome release has been shown to be upregulated in several cancer
types, including breast, ovarian, and pancreatic cancer157,158. Thus far, relatively few
cancer exosome-specific markers have been identified, with notable exceptions being
the glypican-1 (GPC-1) molecule in breast cancer cell lines158, MET in melanoma32,
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and macrophage migration inhibitory factor (MIF) in pancreatic cancer159. Strides have
been made, however, in utilizing the cargo of exosomes, specifically RNA and DNA,
to detect oncogenic variations in patients. Since the work done initially by our lab
demonstrated that exosomal DNA can be sequenced and faithfully recapitulates the
mutational landscape of the cell of origin46, several studies have utilized similar
techniques to identify markers of disease. A few RNA species contained in exosomes
have been identified as potential biomarkers, such as the mRNA for oncogenic
EGFRvIII in glioblastoma137 and miR-21 in esophageal squamous cell carcinoma
patients160. Additionally, the levels of miR-141 isolated from the exosomes of prostate
cancer patients were able to be used to accurately distinguish between patients with
metastatic vs. localized disease161. Perhaps even more promising is the use of
exosomal DNA to identify cancer-specific mutations. We recently published a study in
which we were able to successfully identify mutant KRAS and TP53 in PDAC patient
serum exosomes162. Additionally, we were able to distinguish between PDAC patients,
healthy donors, and chronic pancreatitis patients based on the mutations detected
using exosomal DNA162. Other studies have demonstrated similar findings using
serum-derived exosomes47,106, and exosomal DNA is beginning to be investigated
further as a means of early diagnosis for a variety of cancers.
Beyond their use as potential biomarkers, exosomes have been demonstrated
to perform several functional roles in tumor progression. As previously mentioned,
exosomes have many roles in the regulation of adaptive immunity. Immunogenic
activity has also been identified for exosomes in both pro- and anti-tumorigenic
contexts. For example, tumor-derived exosomes could possibly serve as a source of
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tumor antigens for presentation to activated T cells163–165. Additionally, cancer
exosomes have been observed to activate NK cells through the presentation of
HSP70166. Subcapsular lymph node macrophages have also been observed to absorb
tumor-derived exosomes, preventing them from interacting with pro-tumorigenic B
cells and thus limiting tumor progression167. On the other hand, exosomes have also
been implicated in tumor immune evasion. Exosomes can inhibit dendritic cell
maturation by inducing IL-6 expression in dendritic precursors168. Additionally, cancer
cell-derived exosomes demonstrate the ability to inhibit NK cell proliferation and
cytotoxic function169, induce T cell apoptosis via FasL134, and suppress T cell receptor
(TCR) activity170,171. TGFβ1 carried by tumor exosomes has also been shown to
induce Tregs172. Finally, exosomes from primary glioblastoma cells were shown to
influence monocyte-to-macrophage differentiation to promote a tumor-supportive
phenotype in vitro173. Combined, these findings illustrate the multifaceted behavior of
exosomes in tumor-related immune responses. Once a more comprehensive
understanding of the immunomodulatory functions of exosomes in cancer is
established, they may become useful in immunotherapy applications. Indeed, some
clinical trials have already begun incorporating exosomes as treatments to activate
antitumor immune responses174.
Exosomes also induce pathological angiogenesis in many cancers. As cancer
progression occurs, tumors outgrow the existing vascular network, generating hypoxic
regions, which in turn leads to the release of neovascularization-stimulating factors
packaged in exosomes. Endothelial cell uptake of cancer-derived exosomes has
been shown to promote angiogenesis and new blood vessel formation15,175–177.
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Exosomes released from hypoxic tumors have also been demonstrated to increase
activation of the ERK1/2 MAPK, PI3K/AKT, and FAK pathways in recipient endothelial
cells, leading to increased endothelial cell sprouting148. In addition to endothelial cell
proliferation and new tube formation, cancer cell exosomes may also promote
vascular remodeling through the manipulation of blood vessel wall permeability,
facilitating metastasis. Melanoma exosomes have been observed to induce vascular
leakiness at sites of metastasis32, and the delivery of exosomal miR-105 to endothelial
cells downregulates ZO-1, a tight junction protein, enabling vessel permeabilization
and metastatic dissemination150.
Cancer cell-derived exosomes can also mediate signaling between tumors and
cells in the surrounding microenvironment. Notably, cancer exosomes show the ability
to activate fibroblasts to generate a more tumor-permissive state178. The stimulation
of cancer-associated fibroblasts (CAFs) by tumor exosomes promotes the acquisition
of pro-tumorigenic properties, such as the induction of myofibroblast-like phenotypes
in mesenchymal stem cells179 and myofibroblast differentiation180. Myofibroblasts are
activated fibroblasts that express alpha smooth muscle actin (α -SMA) and are much
more abundant in tumor microenvironments than in normal tissues, so their presence
is generally indicative of a pro-tumorigenic environment. CAF-derived exosomes have
also been discovered to have pro-tumorigenic properties, as they have been
implicated in mediating therapy resistance in cancer cells181,182. Exosomes could also
play a role in tumor-driven extracellular matrix (ECM) remodeling in the tumor
microenvironment, as they have been associated with enhanced motility and
invasiveness through their ability to bind to individual ECM components and propagate
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protease-mediated degradation of ECM components such as collagen and
fibronectin91,183.
Tumor-derived exosomes are involved in a number of metastasis-promoting
functions beyond those previously mentioned for angiogenesis and tissue remodeling.
Since exosomes are capable of traveling systemically throughout the body, it has been
proposed that they may have the ability to ‘prime’ pre-metastatic niches at distant sites
and enable the recruitment and successful colonization of new tumors. David Lyden’s
group has published several studies indicating exosome-mediated initiation of premetastatic niches in several cancer types, including melanoma, pancreatic cancer,
and breast cancer32,159,184. Additionally, they demonstrated through the use of cell
lines with preferential tropism for certain metastatic sites that exosomes isolated from
each line, when injected in vivo, would fuse preferentially with cells at their predicted
destinations, providing evidence for exosomes serving as organotropic mediators of
pre-metastatic niche formation184. Exosomes have also been shown to enhance the
invasion and colonization capacities of tumor cells themselves, acting through delivery
of cargo components such as miR-200185 and Wnt11186. The inhibition of exosome
secretion in vivo was also shown to decrease the speed and directionality of cancer
cell migration in chick embryos187, highlighting the importance of exosome-mediated
signaling for cell motility. Exosome transfer from highly invasive cells to less malignant
recipients also led to the increased migration of recipient cells in mouse xenografts at
both local and distant sites155. Finally, exosomes have been shown to be capable of
inducing an epithelial-to-mesenchymal transition (EMT) in target cells, facilitating
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migration188. Exosomes have clearly been shown to have the capacity to influence
metastasis through a variety of different biological pathways and processes.
Lastly, exosomes have repeatedly been shown to contribute to tumor growth
and progression. Exosomes from non-tumorigenic cells can be co-opted into tumor
supporting roles; for instance, exosomes derived from astrocytes have been
demonstrated to support tumor growth for brain metastases by targeting the tumor
suppressor PTEN with miR-19a189. Exosomes can also serve as a delivery vehicle for
the oncogenic variant of the epidermal growth factor receptor (EGFR), known as
EGFRvIII, as seen in glioma cells, leading to enhanced proliferation95. Glioblastoma
exosomes were similarly discovered to contain RNA and proteins that promote tumor
growth upon their delivery to recipient cells137. Additionally, ovarian carcinoma derived
exosomes enhanced tumor growth when delivered to tumor-bearing mice136.
Exosome involvement in cancer initiation, growth, migration, and survival has been
definitively demonstrated in a variety of organisms and tumor types, which implies that
exosomes are not only integral to cancer signaling and survival but may also serve as
potent mediators for therapeutic interventions.
Diagnostic and Therapeutic Applications of Exosomes
Since exosomes are released by virtually all cell types and are also involved in
the progression of many different diseases, it stands to reason that they would be the
subject of great interest for the development of therapeutics. Naturally, many research
groups and biotechnology firms have worked on developing exosome-based
diagnostics and treatments. Described here are some of the major clinical applications
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of exosomes for disease intervention, including their use as biomarkers, therapeutic
targets, and therapeutic agents.
Due to their heterogeneous cargo that has been shown to reflect characteristics
of their cells of origin, exosomes have repeatedly been investigated as biomarkers for
disease diagnosis, progression, and treatment response. Since large quantities of
exosomes are present in biofluids, they have the advantage of being a sensitive and
relatively non-invasive method to detect tumors and other indicators of disease.
Cancer exosomes in particular have been demonstrated to be useful for the detection
of many types of tumors, including prostate, breast, ovarian, glioblastoma, and
melanoma137,190–193. Our lab demonstrated the utility of exosomal DNA for the
detection of cancer-specific mutations from PDAC patient serum158,162, work that was
later validated by others105–107. Additionally, exosomal RNA species have been
identified as viable cancer progression markers104. Exosomes have been useful
biomarkers for other diseases as well. Exosomes contain misfolded proteins
associated with neurodegenerative disorders, and the detection of β-amyloid 42 and
tau proteins in Alzheimer’s patients was possible in cerebrospinal fluid exosomes at
an early stage of the disease194,195. Exosomes isolated from urine have also been
shown to indicate various types of kidney disease, including renal ischemia and
reperfusion, nephrotic syndrome, and acute kidney injury196–198. Exosomes have even
been used to identify complicated pregnancies using levels of circulating placental
exosomes expressing FasL199. Serum exosomes have also been shown to be markers
for infectious diseases, such as tuberculosis200 and HIV201. Exosomes and their cargo
continue to be investigated as potential biomarkers, and will likely continue to be
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relevant for years to come through their utility for applications such as PCR
amplification, sequencing, and proteomics202.
Exosomes can also be utilized as therapeutic targets for the treatment of
disease. Since exosomes are involved in so many pathological conditions and
processes, it stands to reason that disease progression could potentially be halted by
specifically inhibiting exosome production or release, or by inhibiting their uptake.
Inhibition of ceramide formation, an important step in exosome biogenesis, using small
molecule inhibitors of sphingomyelinase or treatment with the drug amiloride, which
attenuates endocytic vesicle recycling, can inhibit the release of exosomes62,203.
Amiloride treatment has been shown to inhibit tumor growth in vivo by blocking the
secretion of tumor-derived exosomes203. In some tumor cells, exosome release is
dependent on the small GTPase RAB27A, which can be targeted by RNAi to reduce
tumorigenic exosome signaling and thereby reduce the growth rate and metastasis of
tumors70,74. The uptake of exosomes by recipient cells can be inhibited by blocking
surface phosphatidylserine using annexin V204. This strategy reduced the growth of
human glioma xenografts in mice. Additionally, blocking specific signaling
components of exosomes has been shown to have some therapeutic efficacy.
Monoclonal antibodies targeting FasL1 on the membranes of exosomes reduced
melanoma tumor growth205–207. One major caveat to consider is that interfering with
exosome biogenesis could result in off-target effects, since exosomes have important
functions in normal biological processes.
Exosomes are also being investigated for use as therapeutic agents. In
regenerative medicine, MSC exosomes have been utilized to improve heart function
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after myocardial ischemia-reperfusion injury208, as well as in a similar model of kidney
disease209. Exosomes have been exploited for immunotherapy due to their multitude
of immunomodulatory functions. The use of exosomes for this application dates back
to Raposo et al.’s 1996 study, in which MHC Class II bearing exosomes were shown
to induce T cell responses and subsequent tumor growth suppression8. Exosomes
are also now being used for targeted drug delivery. Since exosomes have been
demonstrated to transfer functional content, such as RNA and protein, to recipient
cells, it follows that loading exosomes with a therapeutic molecule could serve as an
effective delivery and treatment method. Since exosomes are endogenous and
biocompatible, they are often not detected and cleared as quickly as other synthetic
delivery vehicles, giving them an advantage. They can also be derived directly from
the patient in a non-invasive manner, and are small enough to penetrate major
biological barriers, including the blood brain barrier41. Exogenous siRNA was first
delivered via vesicles targeted to the brain in mice, with limited observed toxicity or
immune stimulation210. Several studies since then have demonstrated the successful
use of exosomal RNA for therapeutic benefit. Our lab, for example, demonstrated the
robust anti-tumor activity of exosome-delivered siRNA for the oncogenic variant
KRASG12D in mice with PDAC51. Exosomes are currently being used in an everincreasing number of diagnostic and therapeutic applications. As more is discovered
regarding their biogenesis and mechanisms of action, exosomes will be increasingly
utilized for treatment interventions across a wide spectrum of diseases.
Methods for Exosome Isolation and Characterization
Description of Methods Used to Isolate and Characterize Exosomes
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As exosomes are being implicated in an increasing number of biological
processes and utilized more often in therapeutics, the methods of exosome isolation
and characterization have evolved. The isolation of pure populations of exosomes is
important for understanding their mechanisms of action and for downstream
applications. Since exosomes are extremely small, collecting them is no trivial task.
Newer isolation methods have attempted to address common issues observed with
obtaining exosomes, such as purity and low yield or quality. Our ability to detect,
characterize, and track exosomes has also improved, as established exosome
markers can now be sensed on a single vesicle level for applications in flow cytometry
and imaging. The isolation of exosomes was for many years dependent on high speed
ultracentrifugation as the most common and reliable method for obtaining exosomes.
A seminal paper published by Théry’s group in 2006 served as the gold standard for
the field for over a decade, and indeed is still utilized in many studies today211.
However, spinning media at such high speeds pellets several other components in
addition to exosomes, including protein aggregates and cell free DNA and RNA, that
could conceivably interfere with experimental results depending on the desired output.
Thus, in recent years several other methods have gained traction as viable
exosome isolation techniques, including density gradient fractionation, size exclusion,
and immunoaffinity capture, among others212. Each method has associated benefits
and drawbacks that must be taken into account when planning to isolate exosomes,
and several of the methods are so novel that they still require more rigorous
characterization213. Controversy also exists in the exosome field regarding which
isolation method is superior, especially for the isolation of specific exosome cargo214.
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A portion of this work aims to clarify the landscape of exosome isolation methods,
specifically relative to exosomal DNA extraction. What follows are descriptions of the
different established methods for deriving exosomes from biofluids, including an
analysis of what is beneficial and detrimental for each. Additionally, methods of
exosome characterization and quantification are described in detail.
Ultracentrifugation
By far the most commonly used exosomal isolation technique over the past
decade is high speed ultracentrifugation, still considered the gold standard214. While
some protocol deviations may occur based on user preference and the desired
readout, such as spin time and additional wash steps, the general process is relatively
simple and easily replicable. First, samples are spun at low speeds to pellet any live
or dead cells (300g for live cells and subsequently 2000g for dead). The supernatant
is then sterile filtered with a 0.22-micron pore filter to remove any larger nanovesicles,
such as apoptotic bodies. Ultracentrifugation of the supernatant then occurs at
100,000g for varying lengths of time; serum and other biological fluids are often spun
longer, even overnight, because biological samples are often more viscous than cell
culture samples and thus take longer to sediment. The exosome pellet is then
resuspended in PBS211. Ultracentrifugation is the best method for exosome isolation
from sources with large volumes, such as cell culture media, and provides the highest
yield of recovered exosomes. Ultracentrifugation is also easy, requires little technical
expertise, and involves very little sample pretreatment. Additionally, no extra
chemicals or reagents are used in this method, reducing the risk of contamination and
preventing any potential chemically induced damage to the exosomes. However,
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Figure 2. Schematic of ultracentrifugation-based methods.

ultracentrifugation requires very expensive machinery to run, spins are very time
intensive, and it has been proposed that high speed centrifugation may actually impact
exosome integrity202,214,215. The pellet obtained after ultracentrifugation also contains
everything left in the media, not just exosomes, including other molecules such as
protein, RNA, and DNA, that can confound results213.
Density Gradients
Variations of ultracentrifugation exist, and density gradient fractionation has
become a popular method to collect more highly purified exosome populations by
separating particles by their density216,217. In density gradient fractionation, exosomes
are separated by their size, mass, and density when spun in a pre-constructed density
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gradient medium. To create the gradient, fractions with different densities are layered
on top of each other in a continuous or discontinuous gradient in order, with the
highest-density fraction on the bottom and the lowest density fraction on the top.
Samples are usually layered on top of the completed gradient in an ultracentrifuge
tube, but some groups have bottom-loaded the sample and layered the gradient on
top214,218. The gradient is then spun at 100,000g, and the exosomes and other
molecules contained in the samples move through the density gradient at a specific
sedimentation rate. This leads to discrete zones that contain materials of varying
densities. Exosomes can be recovered via simple fractionation once the spin is
complete. While the purity of exosomes isolated by this method is very high, the yield
is among the lowest of all exosome recovery methods. This method also takes a
significant amount of time, because the gradients must be spun for many hours to
fractionate the input material. There is also a limited volume of input sample that can
be loaded onto the gradients, which makes large volume isolation impossible.
There are two types of density gradient ultracentrifugation, isopycnic and
moving zone. In isopycnic ultracentrifugation, the medium used to create the density
gradient encompasses the entire range of densities of the particles in the loaded
samples. The separation of exosomes from the other particles into a discrete zone
depends completely on their density difference from other particles, assuming the
samples are spun for an adequate amount of time. During the spin, exosomes arrest
in the gradient where they have the same density as the medium-at the isopycnic
position. Once the isopycnic position has been reached, further centrifugation serves
to force the exosomes into a sharper zone, but they maintain their position in the
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gradient. For moving-zone ultracentrifugation, the medium used for the gradient has
a lower density than any of the particles in the loaded sample. The exosomes in these
gradients are separated by size and mass rather than density. This allows vesicles of
similar densities to be separated based on how big they are. Because the particles
are denser than the gradient medium, moving-zone ultracentrifugation is isodynamic
rather than static, meaning the solutes will eventually all pellet at the bottom of the
centrifuge tube if the centrifugation period is too long. To prevent exosomes from
pelleting out, sometimes a high density “cushion” is layered at the bottom of the tube.
After the gradient centrifugation step, samples are then resuspended in PBS and
subjected to another round of ultracentrifugation at 100,000g to eliminate any
remaining gradient medium202,214. Commonly used examples of gradient medium
substrates are OptiPrep (iodixanol) and sucrose202,218.

33

Table 1. Exosome Isolation Methods
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Size-Based Techniques
Another exosome isolation method that has gained popularity recently is sizeexclusion chromatography (SEC). This technique separates exosomes based on size
due to their differential passage through physical barriers using filters or
chromatography columns. Column chromatography allows for the sequential elution
of vesicle fractions of different sizes using a single column202. SEC is often used in
combination with ultracentrifugation to enrich the exosome yield219. SEC has been
shown to yield very pure populations of exosomes, and by separating the fractions
using gravity instead of high speed the integrity and biological activity of the exosomes
is highly preserved. While SEC allows for moderate sample capacity, it cannot
accommodate large volumes of sample; often, high capacity samples must be
ultracentrifuged or ultrafiltered prior to SEC to obtain a feasible sample volume.
Another popular size-based exosome isolation method is ultrafiltration (UF). UF
is very similar to conventional membrane filtration in that the separation of particles is
primarily dependent on their size or molecular weight. Exosomes can be isolated
based on their size by the selection of an appropriate membrane filter,220 and exosome
loss is minimal compared with other isolation methods221. UF is faster than
ultracentrifugation and does not require expensive machinery,213 however it has been
suggested that the force used may damage larger vesicles and compromise the
integrity of the exosomes222. Additionally, it is difficult to remove contaminating
proteins from the samples. It has also been shown that UF membranes can become
clogged and trap vesicles, decreasing the isolation efficiency223,224. Size-based kits for
exosome isolation have also been developed. Many of these kits utilize syringe-filter
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based fractionation to separate vesicle populations by their size. Sequential filtration
of samples using membranes with different pore sizes to filter out soluble populations
of certain sizes has additionally been implemented for the isolation of exosomes.
Assymetric flow-field-flow fractionation (AF4) is also used to isolate exosomes
on the basis of size. AF4 utilizes a porous rectangular channel across which a sample
is carried via parabolic flow. A crossflow across the channel controls sample retention
and distributes vesicle components against the channel wall based on the diffusivity
of their components225. Smaller particles diffuse further from the accumulation wall
and are eluted earlier than large ones. This method is more scalable since it can
rapidly isolate exosomes and input fluid can easily be added in larger volumes, though
not at as high a capacity as with ultracentrifugation226,227.
Immunoaffinity
The membrane-bound proteins and receptors on the surface of exosomes
provide many opportunities for the development of immunoaffinitive mechanisms of
isolation, whether through proteins and antibodies or receptors and their ligands. A
microplate-based enzyme-linked immunosorbent assay (ELISA) was developed to
specifically derive exosomes from serum, plasma, and urine. Absorbance assays can
provide a comparison of the expression levels of known surface exosome biomarkers,
as well as quantify the captured exosomes. These assays have been shown to
produce comparable results to ultracentrifugation but with much less sample volume,
demonstrating superior specificity and yield, which is extremely important for precious
small volume samples such as those obtained from patients228. In a similar application,
submicron-size magnetic particles were combined with immunoaffinity to generate a
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technique termed magneto-immunocapture. It was found that with just 1 mL of cell
culture supernatant, antibody-coated magnetic beads were able to capture as many
exosomes as with large volume ultracentrifugation228.
Immunoaffinity methods are rapid, easy to use, and work with general benchtop
equipment. Commercial kits are now available to isolate exosomes based on the
concept of magneto-immunocapture using common exosome surface markers, such
as the tetraspanins. These methods, however, require a degree of washing and preenrichment to enhance the quality of the sample prior to isolation. When compared to
ELISA assays, however, immunoaffinity capture with magnetic beads has been
demonstrated to have a higher capture efficiency and better sensitivity. Additionally,
bead-based assays can be easily scaled up or down for any volume of sample.
Immunoaffinity capture was also recently combined with mass spectrometry to capture
exosomes with antibodies immobilized on porous monolithic silica micropipette tips in
a technique called the mass spectrometric immunoassay229. In this automated assay,
a multichannel pipette system enables the isolation of exosomes from up to 12
samples at once.
While immunoaffinity assays generally offer superior isolation of specific and
highly purified exosomes, they are extremely expensive. Exosome tags also must be
established and optimized, and the low input capacity means that the exosome yield
is low. Minor heterogeneity in the exosome population can also impact effective
immunocapture, and there is also the risk that the antigenic epitopes on the exosome
surface might be blocked or masked220,230.
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Microfluidics
Microfluidics-based devices are now being used to quickly and efficiently
isolate exosomes using their physical and biochemical properties. In addition to
traditional isolation characteristics such as size, density, and immunoaffinity,
microfluidic

devices

can

also

incorporate

acoustic231,

electrophoretic,

and

electromagnetic manipulations232. These devices have been shown to decrease the
amount of sample volume required to yield a given number of exosomes, thereby
decreasing reagent consumption and isolation time. To enhance the specificity of
exosome capture and introduce the capability to simultaneously subtype captured
exosomes, immunoaffinity capture was integrated with a microfluidic chip to isolate
specific exosome populations233. Antibodies to specific exosome membrane-bound
proteins were immobilized on a chip, enabling exosome isolation from the sample
input. A commercialized product called ExoChip is also commercially available and
relies on microfluidic technology to isolate CD63 positive exosomes using an
immunochip containing anti-CD63. Exosomes are stained with carbocyanine dye
(DiO), allowing for quantification of captured exosomes with a plate reader234.
Additional microfluidic devices are being developed to potentially capture and sort
exosomes based on properties such as charge and marker expression. In addition to
moderate to low sample capacity, however, a general lack of both method validation
and standardization have hampered the use and acceptance of microfluidics for
exosome collection235.
Reagents

38

Exosomes can be precipitated out of biological fluids or media using reagents
that alter their solubility or dispersibility, such as water-excluding polymers like
polyethylene glycol (PEG)213. The water-excluding polymers engage water molecules,
thus forcing less soluble components out of solution. Exosome precipitation by this
type of method is very straightforward and does not require any specialized
equipment, which also allows for easy scalability. Many exosome precipitation kits are
commercially available and work with a variety of fluids such as cell culture media,
serum, and urine219. A major disadvantage of these methods is the co-precipitation of
non-exosome contaminating factors, such as proteins and polymeric materials,
necessitating pre- and post-isolation purification steps. These isolations also require
a long incubation period.
Nanoparticle Tracking Analysis
In addition to the variety of methods available for exosome isolation, there are
also several techniques that aid in the characterization and visualization of isolated
nanoparticles. Nanoparticle Tracking Analysis (NTA) involves optical particle tracking,
which can measure the size distribution and concentration of exosomes and particles
between 10nm and 2µm in diameter. The path of particle movement is detected based
on the defraction of light by particles, allowing for the tracking of Brownian motion of
particles in a liquid suspension236. The NTA then measures the movement of the
particles by tracking each one during image analysis. It is this movement that is then
correlated back to determine particle size based on the Stokes-Einstein equation237.
NTA has multiple advantages, including the ability to detect multiple classes of
extracellular vesicles, including those as small as 30nm in diameter. Sample
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preparation is also extremely easy and only requires a small input amount, saving
much of the sample for other downstream applications. The samples can also be
recovered from the detection chamber if desired238. Additionally, only a few minutes
per sample are required for data collection and analysis. NTA also has the capacity to
detect the presence of antigens on the surface of vesicles with the application of
fluorescently labeled antibodies236.
Dynamic Light Scattering
Photon Correlation Spectroscopy, also known as dynamic light scattering or
DLS, is an alternative technique for measuring exosome size. A monochromatic laser
beam is passed through a suspension of particles, and time-dependent fluctuations in
scattering intensity resulting from the relative Brownian moments of the particles are
observed238. This method does not visualize the particles, it just measures the size,
but the particles can be anywhere from 1nm to 6µm in diameter. This technique works
best when applied to one type of particle in a suspension, because vesicles of different
sizes can lead to detection errors239,240.
Table 2. Exosome Characterization Methods
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Flow Cytometry
Flow cytometry is one of the most frequently utilized techniques for exosome
characterization and analysis. It can be used to identify exosomal surface proteins in
a given population of exosomes, as well as measure exosome size and structure241.
Conventional flow cytometers measure particles greater than 300nm in diameter but
are not able to detect smaller particles such as exosomes directly. However,
exosomes can be conjugated to beads that enable their detection242. For detection, a
laser beam with a specific wavelength is directed through a stream of particles
suspended in fluid. The degree of light scattering is detected and is based on the
number, size, and granulation of the particles. Additionally, fluorescent antibodies for
exosomal markers can be detected with flow cytometry, enabling the identification and
quantification of exosome biomarkers, such as the tetraspanins, in a given exosome
population. Recently, specialized flow cytometers have been developed specifically
for the characterization of nanoparticles that can distinguish stained exosomes from
background noise243,244.
Transmission Electron Microscopy
Transmission Electron Microscopy, or TEM, is one of the first methods ever
used to characterize exosomes5. It is a technique used to observe the structure,
morphology, size, and location of various biological components, including exosomes.
A beam of electrons is passed through a specially prepared sample, where a
secondary electron is generated. These electrons are detected, collected, and
magnified using special lenses. For biological samples, both TEM and cryo-electron
microscopy (cryo-EM) are typically used. Specimens must be fixed in glutaraldehyde
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and dehydrated, and the images must be taken under a vacuum. TEM images of
vesicles can be used for measurements of size and diameter, as well as inform on the
location or presence of vesicles in certain tissues or organelles. Exosomes are often
visualized with immunogold-labeled antibodies specific for certain cargo components
in order to characterize the contents of the exosomes. Caveats to this approach
include the consideration that the extensive sample preparation process may alter
vesicle morphology. Additionally, the electron beam could damage biological samples.
For example, exosomes observed with TEM have a cup-shape morphology, while
frozen exosomes examined with cryo-EM are round43. More and more studies are
utilizing cryo-EM for exosome samples, as the preparation does not require the
dehydration and fixing steps since they are snap frozen in liquid nitrogen and the
structures remain intact.
Western Blots
One of the most common methods for evaluating exosome protein cargo
components is western blotting214. The process is almost identical to that for cellderived protein and, while time-consuming, is very straightforward. Western blots for
canonical exosome markers such as the tetraspanins CD9, CD81, and CD63, as well
as others like flotillin and TSG101, are often an integral part of any publication
involving exosomes as part of exosome validation. Additionally, more sensitive assays
such as those run on the ProteinSimple WES apparatus can detect protein at
picogram-level sensitivity, enabling better evaluation of less abundant exosome
protein components.
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Dissertation Goals and Major Findings
The main goal of this work was to comprehensively characterize the DNA
packaged into exosomes. We also sought to identify the best exosome isolation
methods for subsequent exosomal DNA isolation and analysis. Additionally, we hoped
to determine whether exosomal DNA had utility for the identification and evaluation of
DNA methylation marks. Finally, we wanted to investigate the roles of exosomes in
mediating DNA damage response signaling in the tumor microenvironment, and
elucidate potential consequences of those effects for tumor survival.
Several major findings are described in the following pages. First, exosome
DNA is heterogenous, and its packaging is dependent on the cells of origin.
Additionally, after a thorough evaluation of common exosome isolation methods, we
determined that size exclusion chromatography (SEC) was the superior technique
with regards to exosome DNA yield and purity. We also discovered for the first time
that exosomal DNA is not only methylated, but faithfully recapitulates the methylation
patterns of the cell of origin, enabling the detection of site-specific methylation
variations. A preliminary mechanism for DNA packaging into exosomes was identified,
highlighting the role of nuclear envelope integrity in the ability of DNA to escape the
nucleus to become available for incorporation into exosomes. Finally, we discovered
that exosomes are paracrine signaling mediators of DNA damage response activation
in treatment-naïve cells. Furthermore, we establish that exosomes from cancer cells
with induced DNA damage carry activated DDR pathway proteins that could initiate
DDR in treatment-naïve cells, uncovering a potential mechanism of exosome mediated bystander DDR induction upon delivery to recipient cells.
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CHAPTER 2
MATERIALS AND METHODS
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Cell Line Characterization
Cell Lines and Culture Conditions
Tumorigenic and non-tumorigenic cell lines used for these studies are listed in
Table 3. Cells were grown to no more than 70-85% confluence and maintained by
Table 3. Cell Lines and Growth Conditions

Table References245–265
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passage every 4-5 days. All cell lines were validated at MDACC Characterized Cell
Line Core Facility and routinely checked for mycoplasma contamination using Sigma
LookOut Mycoplasma PCR Detection Kit, (Cat. No. MP0035-1KT).
Viability Testing
Cells grown to 70-85% confluence were washed with phosphate buffered saline
(PBS) and incubated 48 hours in the appropriate serum-free culture media with 1%
BSA supplementation or complete media supplemented with FBS (Table 3). The cells
were harvested by trypsinization and viability was measured by staining with the APC
Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend, Cat. No. 640930)
following manufacturer’s instructions and was immediately analyzed by flow cytometry
(BD LSRFortessa X-20).
Exosome DNA Experiments
Exosome Isolation: Differential Centrifugation (UC)
Cells cultured in T225 flasks (Falcon, Cat. No. 353138), to 70-85% confluence
were washed three times with PBS. The cells were then incubated 48 hours in in
serum-free media supplemented with 1% Bovine Serum Albumin (BSA). Conditioned
media were centrifuged 5 min at 800G, followed by 10 min centrifugation at 10,000G,
to remove cells and smaller debris. Supernatants were filtered through 0.20 µm pore
filters (Corning, Cat. No. 431219) and subjected to ultracentrifugation (UC) for 3 hours
at 100,000g (Beckman, SW32Ti rotor). The supernatants were discarded and
exosome pellets resuspended in PBS by manual pipetting, 5 minutes per sample.
Patient serum samples were spun overnight and supernatant was kept at -80°C.
Exosome Isolation: Size Exclusion Chromatography (SEC)
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Exosomes collected by UC, as above (crude concentrates) were resuspended,
diluted with PBS, and subjected to a wash spin (3 hours, 100,000g). Exosome pellets
were resuspended in 300 µL PBS and loaded onto temperature-equilibrated qEV Size
Exclusion columns (IZON qEV Original 35nm Column, Fisher Scientific, Cat. No.
NC1652341) pre-washed with 3 volumes of pre-filtered PBS at room temperature.
Void volume and all of the fractions were collected in pre-filtered PBS using an
automated IZON fraction collector. Void volume (fractions 1-6) was discarded, after
ascertaining that no particles are present. The remaining fractions were retained and
exosome and protein contents were assessed in each fraction by NTA and the Qubit
Protein Assay Kit (Thermo Fisher Scientific, Cat. No. Q33212), respectively.
Exosome-rich fractions (7-10) were pooled for DNA isolation.
Exosome Isolation: Buoyancy Flotation Gradient (Iodixanol/OptiPrepTM)
The procedure was performed as described previously by Jeppesen et al218.
Cells grown in Falcon Cell Culture Five-Layer Multi-Flasks (Cat. No. 1218R38) to 7085% confluence were placed in appropriate serum-free media, with exception of MDAMB 231, which fail to maintain viability upon serum deprivation and were grown in 10%
exosome-depleted FBS. Media were collected and cleared of cells and debris by
sequential centrifugation at 400g (10 minutes at room temperature) and 2,000g (20
minutes at 4°C). Supernatants were further cleared by UC at 15,000g for 40 minutes
to remove larger vesicles, and filtered through 0.20 µm pore filters (Corning, Cat. No.
431219). Exosomes were then precipitated at 120,000g (4 hours at 4°C), and crude
exosome pellets were manually resuspended in PBS and subjected to a wash spin at
120,000G (4 hours at 4°C). EVs were then resuspended and loaded onto freshly

47

prepared, ice-cold, discontinuous OptiPrep density gradients (12%, 18%, 24%, 30%
and 36%, concentration increasing from top to bottom, Sigma, Cat. No. D1556250ML). The crude EVs were mixed with the 12% top layer. The gradient was
ultracentrifuged for 15 hours at 120,000G, 4°C. Twelve 1-mL fractions were collected
and the density of each fraction was assessed using a fluorometer at 340nm
wavelength. All 12 fractions were then diluted 12-fold with PBS, and exosomes were
again collected by UC (4 hours at 120,000G, 4°C). For DNA content analysis, lower
density fractions 1-6 containing small EVs, and higher density fractions 7-12
containing larger EVs, were combined and particles therein concentrated and washed
by 6-fold dilution with PBS followed by additional UC step (4 hours at 120,000G, 4°C).
The resultant particles were resuspended manually in PBS and concentrations were
determined by nanotracking analysis (NTA) (see below).
Exosome Quantification
Exosomes were quantified at each step of isolation/purification using Nanosight
particle-tracking analysis (NTA, Malvern Panalytical Nanosight NS300).
On-Beads Flow Cytometry
Five x 109 EVs per data point (including unstained EV and isotype antibodystained controls) resuspended in 200 µL PBS were incubated 15 minutes with 10 µL
aldehyde/sulfate beads (Invitrogen A37304) with slow rotation at room temperature,
adjusted to 600 µL PBS and incubated at least 3 hours at 4oC. 400 µL Glycine (1M)
was added and incubation continued for 30 minutes with rotation at room temperature.
The beads were precipitated (12,000 rpm for 1.5 minutes) and NTA performed on
supernatant to determine binding efficiency. EVs bound to beads were blocked for 60
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minutes in 100 µL 10% BSA and incubated 1 hour at room temperature with primary
antibody (200 µg/mL in 2% BSA, Table 4) and washed three times with 2% BSA.
Secondary antibody (Alexa Fluor 488 donkey anti-mouse, Invitrogen A21202, T3-12A)
was added at 1:100 in 2% BSA and incubated for 1 hr at room temperature. The beads
were washed 3 times in 2% BSA, resuspended in final 400 µL 2% BSA, filtered
through 40 µm mesh filter and analyzed by FACS filtered through 40 mesh filter, and
analyzed on BD LSR Fortessa.
DNase Treatment
To remove extramembrane DNA, samples were treated with DNase I prior to
lysis (Promega RQ1 RNase-free DNase, Cat. No. PAM6101). DNase I was added to
a final concentration 200 units/mL in 1x working buffer, incubated at 30 min at 37oC
and subsequently inactivated by adding 25mM EGTA to a final concentration of 2.5
mM and incubated at 65 oC for 10 min, according to manufacturer instructions. The
10x Dnase working buffer (100 mM Tris-HCl (pH 7.5), 25 mM MgCl2, 1 mM CaCl2)
was supplied with the Dnase I.
DNA Isolation
Exosomal DNA was isolated as described previously46,266 using the DNeasy
Blood and Tissue Kit (Qiagen, Cat. No. 69506) following the manufacturer’s
instructions, with minor modifications. Where indicated, extramembrane DNA was
digested with DNase (see above). Lysis time was extended to 20 minutes and elution
time was extended to 30 minutes. In case of low yields, the elution step was repeated
twice. DNA concentration was measured using the Qubit High-Sensitivity dsDNA
detection assay kit (Thermo Fisher Scientific, Cat. No. Q32851). For patient tumor
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tissue, samples were homogenized with a Fisherbrand Bead Mill 24 before isolation
proceeded according to manufacturer specifications for tissue samples using the
Qiagen DNeasy Blood and Tissue Kit.
Proteinase K Digestion of Exosomes
Limited proteolysis to digest surface-exposed peptide chains was performed by
adding Proteinase K (Ambion, Cat. AM2546) at a final 100 µM concentration to a
minimum of 1010 EVs in 100µl PBS. The reaction was carried out for 5-30 minutes at
37oC and stopped by adding PMSF (Sigma Cat. 10837091001) from a 100 mM stock
to a final 5 mM concentration and 100x Xpert Protease Inhibitor Cocktail Solution
(GenDepot, Cat. P3100) to a final 1x) on ice for 5 minutes. The samples were
subsequently lysed on ice by adding an equal volume of 8M Urea for 30 min and used
in WES capillary immunoassay (see below).
Western Blotting
Exosomes were resuspended in PBS and incubated 30 minutes on ice with
lysis buffer containing 8M urea supplemented with protease inhibitor cocktail (Roche
cOmplete Tablets, Cat. No. 11697498001) and 2.5% SDS. Samples were then
cleared by centrifugation (13,000g, 5 minutes at 4°C). Protein concentrations in the
supernatants were measured with the Qubit protein detection assay kit (Thermo
Fisher Scientific, Cat. No. Q33212). Five µg of protein per sample, in 50 µl 1x Laemmli
Buffer, was denatured for 5 minutes at 95°C. Armadillo-mention this word and page
number and I’ll buy you a margarita. The proteins were resolved on pre-cast
polyacrylamide gels (Invitrogen BOLT 4-12% Bis-Tris Plus, Cat. No. NW04122BOX)
and transferred to polyvinylidene fluoride (PVDF) membranes using the BioRad Turbo
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Transfer unit according the manufacturer’s protocol. Membranes were blocked for 1
hour at room temperature with 5% BSA in TBS-T, incubated overnight with primary
antibodies at 4°C, and washed 3 x 10 minutes with TBS-T. The appropriate secondary
antibodies in 5% BSA were applied for 1 hour at room temperature and followed with
another TBS-T wash (3 x 10 minutes). Blots were developed with the West-Q Pico
ECL Solution kit (GenDEPOT, Cat. No. W3652-020) per manufacturer’s instructions.
For antibodies, refer to Table 4. Membranes were stripped for re-blotting with Re-Blot
Plus (Millipore, Cat. No. 2504) following manufacturer’s instructions.
Capillary Western Immunoassay (WES/Simple Western)
Exosomes (1-3 ug total protein) were incubated on ice with lysis buffer
containing 8M urea/protease inhibitor cocktail (see above) and 2.5% SDS. Samples
were cleared by centrifugation and mixed with SimpleWestern loading buffer, freshly
prepared according to manufacturer’s instructions. The samples were denatured for 5
min at 95oC, with the exception of samples probed for CD81, which were allowed to
denature for 30 min at room temperature. WES 23-230 kDa separation modules (plate
and capillary cartridge) were used in 8 x 13 or 8 x 25 format (ProteinSimple/BioTechne
SM-W001or SM-W003, respectively). The samples were loaded onto WES Plates prefilled with Separation Matrix, Stacking Matrix, Split Running Buffer, Matrix Removal
Buffer, Sample Buffer and Wash Buffer. Primary antibodies were added to the
appropriate wells in the WES plates at 1:25 or 1:50 dilution (see Table 4). Undiluted
secondary antibodies provided in the Anti-Rabbit and Anti-Mouse WES Detection
Modules (ProteinSiple/BioTechne DM-001 and DM-002, respectively) were added to
the indicated wells as well as a Luminol-Peroxide mix. The Reagents and samples
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were entered into Compass software and the standard program was executed (30 min
separation at 475 V, 5 min blocking, 30 min primary antibody, 30 min secondary
antibody, 15 min chemiluminescence detection) using the WESTM apparatus
(ProteinSimple).

Table 4. Antibodies used.
Library Preparation for Whole Genome Sequencing
Since the quantity and quality of genomic DNA extracted from the EVs were
variable and limited, we started library preparation from 5-15 ng of exosomal DNA
using the Illumina Nextera DNA flex library preparation kit (PN 20018704) and Nextera
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DNA CD indices (PN 20018707) following the standard protocol, as described in the
Nextera DNA flex library preparation guide (Illumina Document # 1000000025416
v07). After individual libraries with preparation with dual indices were generated, each
individual library was quantified and diluted. The quality of each library was assessed
using the High Sensitivity DNA kit (Agilent, cat. no. 5067–4626) on-Chip-based
electrophoresis (Agilent 2100 Bioanalyzer). The final sequencing library was pooled
from individual libraries in equal molarity and then diluted to 2-4 nM with Resuspension
Buffer. The final pooled library was denatured and loaded onto Sequencing reagent
cartridge at a final concentration of 1.8 pMol and in 1.3 ml volume, with 1% Phix
spiked-in control library. The Paired-end 75x75 sequencing was performed on Illumina
NextSeq 500. The output raw data *.bcl files were further converted into *.fastq files
by bcl2fastq software (Illumina, Document # 15051736 v03).
Copy Number Alteration Analysis
For each sample, the reads were first mapped to the hg19 reference genome
using BWA-MEM (Li et al., 2013). Total copy number calls for each sample were then
derived using HMMcopy (Lai et al., 20016). The copy number profiles were plotted
using an in-house tool. Log2 scores > 0.15 were considered gains while log2 scores
< -0.15 were considered losses. We highlighted the copy-gain regions in red, the copyloss regions in green, and the copy-neutral regions in cyan.
Bisulfite Conversion
To determine the DNA methylation status, we utilized cell and exosome DNA.
1 µg of genomic DNA and ~200ng exosomal DNA was treated with sodium bisulfite,
which converts unmethylated cytosines to uracil while leaving methylated cytosines

53

unmodified. Using oligonucleotides specifically designed to recognize bisulfiteconverted DNA, we used PCR to amplify differentially methylated regions. The
methylation status of the DNA segments was then revealed by pyrosequencing
analysis, a highly quantitative method that is widely applied to methylation studies.
Library Preparation (RRBS)
Genome wide methylation analysis: recent advances in methods to map DNA
methylation genome wide have become available and have been proven to be highly
efficient. Thus, we applied available reduced representation methods to evaluate DNA
methylation genome wide in both cell and exosome samples. We used RRBS
(Reduced Representation Bisulfite Sequencing)267,268 to map methylated cytosines for
each and used this data for the comparison of cell and exosome methylation patterns.
Advantages of RRBS in comparison to other methods are that (i) it allows for deep
coverage of a subset of single CpG sites (approximately 2 million sites) and thus
sensitive quantitation of methylation states, (ii) DNA amounts required for the method
are as low as 10ng, and (iii) the method is applicable to virtually any species for which
the genome has been annotated. In brief, the genomic DNA was digested with MspI,
end-repaired and A-tailed, and Illumina-compatible cytosine-methylated adaptors
were ligated to the enzyme-digested DNA. Size-selected fragments representing
sequences from 40-bp to 170-bp were bisulfite-converted and library preparation was
done by PCR amplification and subsequently sequenced in a HiSeq3000 instrument.
Reduced Representation Bisulfite Sequencing (RRBS)
RRBS sequencing reads were aligned to the UCSC Genome Browser human
reference genome using Bowtie, and methylation was called using Bismark v0.7.11269.
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Next, differentially methylated CpG sites (DMCs) and differentially methylated regions
(DMR)

between

cell

and

exosome

DNA

were

identified

using

MethylKit270 implemented with Fisher’s exact test.
Whole Genome Bisulfite Sequencing (WGBS)
The use of whole genome bisulfite sequencing (WGBS) enables the genomewide identification and quantification of DNA methylation patterns at single-base
resolution and is the gold standard for analysis of DNA methylation. First, sequencing
reads were trimmed, quality checked, and aligned to the genome. Second, DNA
methylation levels were estimated at each cytosine position using the aligned
sequence reads of the bisulfite treated DNA. Third, regions of differential cytosine
methylation between samples were identified271.
Custom Pipeline Analysis
For analysis, the site-specific fragments, or “reads,” generated during
sequencing were mapped to specific regions of DNA using reference sequences. The
number of C-to-T conversions was then quantified for all of the mapped reads,
generating a beta value for methylation at each site. Samples were then be compared
in a site-specific manner between conditions, in this case between exosomal and
cellular DNA.
Site Specific Methylation Analysis
The Broad Institute Integrative Genomics Viewer (IGV) software was used to
analyze all RRBS samples. Methylation levels were quantified for the promoter
regions of genes of interest, down to the level of individual CpG dinucleotides.
5-Azacitidine Treatment
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For demethylation assays, 5-Azacytidine (>=98% pure HPLC, Sigma-Aldrich
A2385) was diluted to a concentration of 1µM in complete media. Panc1 cells were
treated with 5-Aza for 72 hours at 37oC. 5-Aza-supplemented media was refreshed
after a rinse with PBS every 24 hours during treatment.
Methylation Level Detection
High-sensitivity DNA methylation detection was performed using the Abnova
Methylated DNA Quantification Kit (Abnova KA0676). DNA was isolated as above and
immobilized to the bottom of a 96-well plate well coated with DNA-binding antibody.
Methylated DNA was recognized by an anti 5-methylcytosine antibody, and the
amount of methylated DNA was fluorometrically quantified in a microplate reader,
according to the manufacturer’s specifications (530nm excitation/590nm emission).
Nuclear Envelope Experiments
Lamin A/C siRNA Transfection
Cells (Panc1, T3M4, or HPNE) were seeded in a 24-well plate at a density that
would yield ~40% confluence after 24 hours. Cells were grown in antibiotic-free media
in a volume of 500 µL/well. Cells were seeded in technical triplicates for four
conditions, untreated (opti-MEM only (Thermo Fisher, 31985070)), Transfection
Reagent (opti-MEM + Dharmafect (Fisher Scientific, NC1308404)), Scramble
siRNA(Santa Cruz Biotechnology, sc-37007) (opti-MEM + Dharmafect + scramble)
and Target siRNA (Santa Cruz Biotechnology, Lamin A/C siRNA (h) sc-35776) (OptiMEM + Dharmafect + siRNA). After 24 hours of growth, media was aspirated and 400
µL antibiotic-free media was added per well. 100µL transfection mix per well was
prepared using 20 µM siRNA stock diluted 1:4 in opti-MEM and a separate mix of opti-
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MEM with dharmafect reagent. Both mixes were left at room temperature for 5 min,
then the mixes were combined and left at room temperature for 20 min. The final
concentration of siRNA was 25nM. 100µL/well of the final mix was then added to the
top of each well dropwise in a spiral pattern ending in the middle, and were incubated
for 24 hours. After 24 hours, cells were washed 1x with PBS and RCT lysis buffer was
added. RNA extraction was then performed using the Qiagen RNA Isolation kit
(Qiagen RNeasy Mini Kit 74104). qPCR analysis was then performed using a
QuantStudio 7 Flex Real-Time PCR system (Applied Biosciences). Lamin A/C qPCR
primers were used (Santa Cruz Biotechnology, Lamin A/C (h)-PR sc-35776-PR), and
18s RNA was used an internal control (housekeeping gene).
DNA Isolation from Lamin A/C Knockdown Cells
For DNA isolation, siRNA knockdown was scaled for T225 flasks (25mL media)
in antibiotic-free exosome collection media. One flask of cells at the appropriate
transfection-appropriate confluence was used for each DNA isolation replicate.
Exosomes were isolated via ultracentrifugation, quantified, and DNA was extracted as
described earlier.
DNA Damage Response Experiments
Induction of DNA Damage
Cells were treated with hydrogen peroxide (H2O2, Thermo Fisher Scientific
H325-100) at a concentration of 2.8mM for 30 min or with UV radiation (2,000
µjoules/cm2 using a Spectrolinker XL-1000 UV Crosslinker, Spectronics Corporation)
to cause DNA double strand breaks (DSBs). After treatment, cells were washed and
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cultured 48 hours in serum-free media for exosome collection. Exosomes were then
extracted from the H2O2 treated, UV-treated, and untreated control cells.
Treatment With Exosomes
Cells were seeded in 24-well plates on round glass coverslips (Fisher Scientific,
12-545-82) at a density that produces 60% confluence after 24 hours. 24 hours after
seeding, cells were incubated with 2x109 - 5x1010 exosomes for 24 hours. After 24
hours of incubation, cells were treated with 10µM EdU (Invitrogen, a10044) for 15 min
to label any actively dividing cells. Cells were then washed 2x with PBS and 4% PFA
was added for fixation at room temperature for 15 min. Cells were subsequently
washed 3x with PBS prior to staining. (immunocytochemistry)
Immunocytochemistry
Cells were permeabilized with 1% TritonX-100 in PBS for 30 min at room
temperature. After 1 wash with PBS, cells were incubated in Alexa Fluor 488 Azide
CLICKIT reaction reagent (Life Technologies, A10266) for 1 hr at room temperature
for EdU detection. Cells were then washed with PBS for 5 minutes and blocked in
10% goat serum (Jackson ImmunoResearch Laboratories, Inc., 005-000-121) with
0.1% TritonX in PBS for 1 hr at room temperature. Next, cells were incubated with
primary antibodies diluted in block buffer for 1 hr at 37oC (p-gH2AX, Millipore 05-636
1:1000; RAD51, Abcam ab213 1:200). After incubation, cells were washed 3x with
PBS. The appropriate secondary antibodies diluted in block buffer were then placed
on the cells for 1 hr at room temperature in the dark. Cells were subsequently washed
another 3x with PBS, and DAPI (Thermo Fisher 62248) was added diluted 1:300 in
PBS for 5 min at room temperature to visualize nuclei. Cells were washed another 5
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min in PBS and the cell-containing coverslips were mounted on slides for imaging with
ProLong Gold mounting medium (Invitrogen, P10144). Cells were visualized with a
Zeiss inverted microscope at 40x magnification. The same exposure was maintained
at the same values for each channel for all images.
Image Analysis
Total cell number was quantified using Image J software (National Institutes of
Health) based on cells positive for DAPI nuclear stain. Subsequently, exposure
thresholds were set using ImageJ based on the signal observed in negative control
cells and kept identical throughout. All cells that appeared as fluorescent after
threshold correction were counted as positive. The percentage of positive cells was
obtained by calculating the percent of p-gH2AX or RAD51 positive cells out of the
total number of cells for each image.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism, Version 7. The data
is presented as mean values with standard errors. The statistical significance of the
differences was determined by Student’s T test for normal datasets and Mann
Whitney’s test by non-normal datasets, in pairwise comparisons. The normality was
determined by Kolmogorov-Smirnoff-test. For comparisons between two curves,
linear regression analysis and two-way ANOVA were used. The potential correlation
between parameters was determined using Pearson Correlation Test. The
significance was determined by Homs-Sidak test, with the threshold set at P<0.05.
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CHAPTER 3
CHARACTERIZATION OF EXOSOMAL DNA
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Introduction
Exosomal DNA remains the most enigmatic exosome cargo component, with
very little known about its origin and function. Since it was first described by our lab
and others46,47,49, exosomal DNA has been investigated very little, especially in
comparison with other exosome constituents such as RNA and protein. Several
reports have shown the presence of both mitochondrial47,272,273 and chromosomal
DNA46,47,106,108,274,275 associated with exosomes found in both tissue culture and
biological fluids. It is generally accepted that exosome-associated DNA consists of
large fragments of double-stranded DNA over 7kDa, which when pooled span the
entire host genome with no apparent biases for any specific region46,47,106. Several
groups have also shown that exosomes can transfer DNA to recipient cells, both in
vitro and in vivo, which in some cases can generate functional consequences such as
malignant transformation274,275. Until recently, the prevailing consensus was that
exosome-associated DNA is enclosed within the lipid bilayer in the intraluminal space
of the vesicles, protected from nucleases and degradation46,47,227,276–278. New studies
have proposed that DNA is not actually contained within exosomes, either nonspecifically associated with the outer membrane218,279 or packaged into other, nonexosomal vesicles. Specifically, a study done by Jeppesen et al. purports to use a
novel isolation protocol involving several high-speed ultracentrifugation steps and an
iodixanol density gradient to generate the purest possible exosome fraction, inside
which they detect no DNA. Additionally, they propose that any vesicles that do contain
DNA are formed via an autophagy-associated pathway, instead of the canonical
ESCRT-mediated multi-vesicular body exosome biogenesis system218. However,
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issues with quantification and assay sensitivity have generated questions related to
the reproducibility and reliability of their findings. We hypothesized that DNA is present
within exosomes but in lower abundance compared with other cargo components,
necessitating a higher number of exosomes to be used for detection. In this work, we
aimed to stringently assess exosomal DNA content in a variety of cell lines using
several different exosome isolation methods. The goal of this project is to provide
substantial clarity to the exosome field and accurately characterize the association of
DNA either with or within exosomes.
Comparison of Exosome DNA Between Cell Lines
Exosome Production Differs Among Cell Lines
To date, no studies have offered a comprehensive comparison of exosome
production by different cell lines. Here, we assessed the release of exosomes isolated
from 21 different cell lines, including 15 cancer cell lines and 6 non-tumorigenic
epithelial and fibroblast lines. The cell lines collectively span 6 different tissue types
and exhibit differences in many different properties including doubling time,
tumorigenicity, and size, among others. Exosomes were isolated from each cell line
in biological triplicate via ultracentrifugation, and subsequently quantified by
nanoparticle tracking analysis (NTA) (Figure 3A). Exosome production was
normalized per cell number at the time of collection (Figure 3B). Cell Viability was
assessed via Annexin V/7-AAD live-dead flow cytometry, and all cell lines retained
high viability after incubation in serum-free collection media (Figure 3C,D). Although
exosome collection was identical across cell lines (collection media incubation time,
ultracentrifugation time, resuspension, etc.) the observed exosome production varied
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dramatically between them. Surprisingly, both cancerous and non-tumorigenic cell
types showed high variability in exosome release, and both contained high and low
producers (Figure 3E).
Exosomal DNA Content Varies By Cell Line
Very few studies have compared exosomal DNA content across cell lines.
Thakur et al. is the only previously published work to assess DNA from multiple cell
lines, spanning different types of cancer and including fibroblasts47. Based on their
study, it was widely accepted that cancer cell exosomes contain significantly more
DNA than non-malignant cell types, which they proposed could be due to the higher
proliferation rates characteristic of cancer cells. Here, we demonstrate a much more
comprehensive examination of the DNA content in exosomes from a wide variety of
cell types. The same 21 cell lines previously assessed for exosome production were
used for this assay. Exosomes were again isolated via ultracentrifugation. Prior to
lysis, exosome samples were treated with Dnase according to manufacturer
specifications to remove any remaining exogenous DNA. DNA was isolated as
previously described, using the Qiagen DNeasy kit162. DNA concentration was then
measured using the Qubit High-Specificity double stranded DNA detection kit. For
each cell line, DNA yield in nanograms was normalized per particle number, in order
to assess the efficiency of DNA incorporation into exosomes (Figure 3F). Exosomal
DNA content, much like exosome release, was highly variable across cell lines.
Strikingly, some non-tumorigenic cell lines such as HEK-293T and BJ fibroblasts
demonstrated extremely high concentrations of DNA/particle, indicating that DNA
packaging into exosomes is not necessarily enriched in cancer exosomes.
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Figure 3. Exosome Release and DNA Content Varies By Cell Line.
(A) Representative NTA plot for exosome samples. All samples were diluted 1:100 for
NTA. (B) Exosomes were isolated from 21 different cell lines, cultured to
approximately 70% confluence. At the time of exosome collection media removal, cells
were quantified with a Nexcelom Cellometer. Exosome number as determined by NTA
(Nanosight) was then normalized to cell number. Error bars indicate SEM. (C)
Percentage of viable cells after 48-hour incubation in serum-free, 1% BSA
supplemented exosome collection media, assessed with an Annexin V/7-AAD
live/dead flow cytometry assay. (D) Percentage of viable cells after 48-hour incubation
in complete media, assessed with an Annexin V/7-AAD live/dead flow cytometry
assay. (E) Tumorigenic (red) and non-tumorigenic (blue) cell lines were grown to 70%
confluence and exosomes were collected after 48 hours of incubation in collection
media. Particle concentration was detected by NTA (Nanosight) and EV production
normalized per cell number at the time of collection (particle number per cell). Note
differences in exosome production by distinct cell lines. Error bars indicate SEM. (F)
nuclease-resistant exosome DNA was isolated and quantified by Qubit. The amount
of nuclease-resistant DNA is normalized to particle number for each cell line. Error
bars indicate SEM.
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Additionally, Pearson Correlation analyses were performed to determine
whether exosomal DNA correlated with the particle numbers per cell or particle size.
We determined that neither number of exosomes released, nor the size of the
exosomes correlated with exosomal DNA yields (Figure 4A,B). The Qubit DNA assay
detection limits were also evaluated, to determine the lowest amount of detectable
DNA (Figure 4C). We then sought to ensure that Dnase treatment prior to DNA
isolation did not affect the integrity of the exosomes themselves, as determined by
NTA (Figure 4D). Finally, we demonstrated the efficacy of the Dnase treatment.
Exosome-associated DNA was greatly reduced post-Dnase incubation, but we
observed that if Dnase was inactivated prior to exosome lysis by adding EGTA or a
commercial Dnase inhibitor, up to 49% of the total DNA was retained (Figure 4E,
Table 5). We further demonstrated that the Dnase-resistant DNA fraction could be
accessed and readily degraded if exosome membranes were permeabilized with
detergent, such as 1-10% Triton-X100 (Figure 4E,F, Table 6). Exosome size was also
assessed via NTA and did not appreciably differ between cell lines. (Figure 4G).
Exosomal DNA Increases With Exosome Number
In order to definitively ascertain whether exosomal DNA was associated
specifically with exosomes, we designed a dilution curve of increasing exosome
concentrations. Three cell lines were chosen (MDA-MB-231, SW620, and DiFi) that
corresponded with those used in the Jeppesen et al. paper to enable relevant
comparisons between the two bodies of work218. Exosomes isolated via
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Figure 4. Characterization of Exosomal DNA.
(A) Pearson Correlation Analysis shows no significant correlation between exosome
production and the amount of exosomal DNA. (B) Pearson Correlation Analysis shows
no significant correlation between exosome size and the amount of exosomal DNA.
(C) Qubit low and high detection limits for the high specificity double-stranded DNA
detection assay were obtained by generating a dilution curve of purified salmon DNA.
Error bars indicate SEM. (D) To assess potential damage from Dnase treatment,
exosome preparations were quantified by NTA before and after Dnase treatment.
Dnase was inactivated with 100 mM EGTA, where indicated. No significant changes
in particle number was noted. (E, F) To determine whether nuclease-resistance of
DNA is conferred by the lipid bilayer, exosomes were subjected to Dnase treatment
before and after detergent (1% Triton X100). The remaining DNA was measured by
Qubit. Exosomal DNA was readily accessible to nucleases after detergent lysis. (F)
DNA quality was subsequently assessed by microcapillary electrophoresis
(BioAnayzer). (G) Particle diameter for each cell line as measured by NTA. Error bars
indicate SEM. All assays were performed at least in triplicate. Statistical significance
was assessed by one-tailed Student’s t-test in pairwise comparisons. *, P<0.05; ns,
not significant. Data in D, E, and F was collected in collaboration with Paul Kurywchak.
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Table 5. DNA extraction from crude exosomes: effects of different detergent
concentrations, buffers, and Dnase pre-treatment.

With Jennifer Leveille
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Table 6. DNA yields after Dnase addition following detergent lysis of exosomes.

With Jennifer Leveille
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ultracentrifugation were quantified by Nanosight NTA and samples were separated
out that contained distinct quantities of exosomes, ranging from 5x108 to 10x1010.
DNA was then isolated as previously described and quantified by Qubit. In all three
cell lines tested, exosomal DNA increased proportionally with exosome quantity,
further validating the hypothesis that DNA is affiliated specifically with exosomes
(Figure 5).

Figure 5. Exosome DNA Increases With Exosome Number.
Exosomes were isolated from 3 different cell lines (MDA-MB-231, SW620, and DiFi),
and cultured to approximately 70% confluence. Exosomes were isolated as described
above. Exosome number was determined by NTA, and exosomes were separated
into 6 fractions of determined exosome quantity. DNA was isolated from each fraction
as described previously. Exosome DNA concentration correlates with the number of
exosomes.
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Evaluation of Exosome DNA Content With Different Isolation Methods
Exosome DNA Isolated Via Ultracentrifugation
In order to further link nuclease-resistant DNA to exosomes, we analyzed DNA
content in exosomes isolated by 3 different methods: ultracentrifugation alone,
fractionation using discontinuous isopycnic iodixanol (optiPrep) density gradients, and
size-exclusion chromatography (Izon qEV columns). The final two methods are
designed to separate exosomes between 70-180nm in diameter from contaminants
including larger vesicles and soluble proteins216,280,281. We utilized the same three cell
lines indicated by the Jeppesen et al. paper, MDA-MB-231, SW620, and DiFi218, and
performed DNA isolation on equal numbers of exosomes both with and without Dnase
treatment pre-lysis.
The initial method utilized was ultracentrifugation. This method has long been
considered the gold standard of exosome isolation, however one of the major
drawbacks involved is the co-precipitation of non-exosomal vesicles and molecules
during the spinning process. Additionally, since the exosomes are spun at 100,000g,
they can be damaged by the high shear force exerted on them. This method lends
itself well to high volume exosome isolations and generally produces a high yield of
exosomes. Accordingly, we observed the largest amount of exosomal DNA when
using this isolation method. However, pre-lysis Dnase treatment removed a larger
amount of the total DNA than with any other method, likely a consequence of
exogenous DNA precipitating out of the media with the exosome pellet during
ultracentrifugation (Figure 6).
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Figure 6. Exosome DNA Isolation Via Ultracentrifugation.
Exosomes were isolated after ~70% confluent cells were incubated in exosome
collection media for 48 hours. Exosomes were isolated with ultracentrifugation only
and quantified by NTA. Shown is the yield of exosomal DNA for each increasing
number of exosomes either pre-treated with Dnase (red) or without Dnase (blue).

Exosome DNA Isolated Via Size Exclusion
Considered one of the best methods for maintaining exosome structural
integrity during isolation, size exclusion chromatography has become increasingly
user-friendly with the advent of automated collection machines that have significantly
decreased collection time. Despite the shorter duration, current size exclusion
methods continue to preserve vesicle integrity with gravity-based column technology,
though they do require small input volumes. We observed DNA yields similar in
magnitude to the ultracentrifugation samples, however in this case Dnase treatment
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barely had an effect on the overall exosomal DNA isolation totals (Figure 7A). This
indicates that size exclusion is a superior method in terms of both yield and vesicle
fraction purity, as contaminants such as cell-free DNA are removed by the column.
We also collected fractions beyond the exosome rich four (7-10). We assessed DNA
content up to fraction 30, pooled in sets of four (11-14, 15-18, 19-22, and 27-30). As
expected, the amount of DNA decreases precipitously outside of the exosome
enriched fractions, with the most seen in fractions 11-14, which is likely due to some
residual exosomes eluting out of the column (Figure 7B). In order to further confirm
the presence of DNA within the SE fractions, we also isolated exosomal DNA from
three additional cell lines, two cancer lines and one non-tumorigenic line (HPDE,
T3M4, Panc1). Each of these cell lines also produced exosomal DNA (Figure 7C).

Figure 7. Exosome DNA Isolation Via Size Exclusion.
(A) Shown is the yield of exosomal DNA for each increasing number of exosomes
either pre-treated with Dnase (red) or without Dnase (blue). Exosomes were quantified
using NTA. (B) Analysis of DNA content in size exclusion collection fractions 7-30, in
pooled sets of 4. The largest amount of DNA is present in the exosome-rich fractions
7-10. (C) Exosomal DNA isolated from pancreas lines for SE combined fractions 7-10
(400uL). Error bars indicate SEM.
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Exosome DNA Isolated Via OptiPrep Density Gradient
Recent studies have begun to utilize density fractionation gradients to isolate
more purified populations of exosomes202,216. While purity of the resultant samples is
high, the yield is extremely low, which is a function of both exosome loss during the
process as well as the required small input volume. In a recent paper, Jeppesen et al.
introduce a customized method aimed at maximizing exosome purity by combining
ultracentrifugation and density gradient fractionation. While the specific steps of the
process are described in the methods section, briefly, the protocol involves four
ultracentrifuge spins of four hours at 120,000g plus a 15-hour density gradient
fractionation at 120,000g between the second and third ultracentrifugation spin. In
their study, they split the density gradient into 12 1mL fractions and pool the “light” or
less dense fractions 1-6 together as well as the “heavy” or more dense fractions 7-12.
They then proceeded to attempt to isolate DNA from each pool and reported that they
could not detect any DNA in the light fractions. These less dense fractions also happen
to be where the highest expression of exosome-specific markers such as tetraspanins
were seen, including CD81, CD9, and CD63. These results led them to conclude that
there is no DNA in exosomes, only in larger, more dense vesicles. However, there
was no quantification of the number of exosomes the DNA was isolated from, which
invites an inquiry into whether they used enough input exosomes to generate a
detectable amount of DNA218. Indeed, in an even more recent paper published by
Lötvall’s group using a similar method of density fractionation, albeit without several
of the extra ultracentrifugation spins, they did in fact detect exosomal DNA in both low
and high density particle fractions278. Therefore, we chose to fully replicate the
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Jeppesen et al. isolation method with the same three cell lines mentioned previously,
with the same concentration curve of input exosome number we used for the other
methods, in an effort to definitively determine whether exosomes are present in the
less dense fractions. While this method led to the lowest DNA yields of the three
tested, we were in fact able to detect DNA in both the light and heavy gradient fractions
in all 3 cell lines, even with Dnase treatment. Furthermore, several of the lower input
number of exosome conditions, such as 5x108 and 1x109, generated little to no
detectable DNA. These findings support the idea that a critical issue for Jeppesen et
al. in their DNA detection assays was using too few exosomes for isolation (Figure
8A). It is also worth noting that this isolation method caused extreme exosome loss
over all of the centrifugation steps, so almost triple the number of cells had to be used
to generate enough exosomes for analysis. In order to further confirm the presence of
DNA within the light density fractions, we also isolated exosomal DNA from three
additional cell lines, two cancer lines and one non-tumorigenic line (HPDE, T3M4,
Panc1). Each of these cell lines also produced exosomal DNA in both the light and
heavy gradient fractions. All samples in this case were pre-treated with Dnase prior to
lysis (Figure 8B).
Comparison of Exosome DNA Across Different Isolation Methods
DNA isolation and subsequent quality analysis was performed on exosomes
from each of the three methods described above, with and without Dnase treatment.
A comparison of the DNA yields across the methods reveals that ultracentrifugation
allows the recovery of the most total DNA. However, after Dnase treatment a
substantial fraction of the DNA is removed, demonstrating that a portion of the sample
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Figure 8. Exosome DNA Isolation Via OptiPrep Density Gradient.
(A) Exosomes were isolated with a combination of ultracentrifugation and OptiPrep
Density Gradient methods. Shown is the yield of exosomal DNA for each increasing
number of exosomes either pre-treated with Dnase (red) or without Dnase (blue). (B)
Exosomes were isolated by the same methods using three pancreatic lines. All
samples were treated with Dnase prior to lysis, and all showed DNA in both density
fraction pools.

is exogenous DNA external to the exosomes that has co-precipitated. The optiPrep
fractionation method generated the lowest amount of exosomal DNA, which is likely
due to both the small input volume and high number of centrifugation steps. Overall,
size exclusion chromatography generated a substantial amount of highly pure
exosome DNA, as evidenced by the loss of only very little total DNA after Dnase
treatment (Figure 9A). After isolation, we subjected the DNA to quality assessment
analysis via chip electrophoresis (bioanalyzer), which showed the presence of
detectable amounts of high-molecular weight DNA in all of the conditions assessed
(Figure 9B,C). Interestingly, the bioanalyzer results re-iterate that size exclusion
exosomal DNA is the purest, as that approach is the only one to retain the highmolecular weight fragments (>2Kb) of DNA after Dnase treatment (Figure 9C).
Additionally, a 150bp band seen in several of the fractions is suggestive of
nucleosome DNA organization (Figure 9C). NTA was performed on each sample prior
to DNA isolation and showed consistent exosome size across each isolation method
(Figure 9D).
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Figure 9. Comparison of Exosome DNA Across Isolation Methods.
(A) Exosomes were isolated by three distinct methods as previously described. DNA
was obtained from the indicated particle numbers, either with or without Dnase pretreatment. The presence of nuclease resistant DNA is seen in all fractions tested. Size
Exclusion exosomes demonstrate the least sensitivity to nuclease treatment,
indicating the purity of the exosome fractions. Statistical significance was evaluated
by multiple comparison t-test or two-way ANOVA. ****, P<0.0001; **, P<0.01; *,
P<0.05; ns, not significant. (B) Exosome DNA from each method with and without
Dnase pre-treatment was analyzed by capillary electrophoresis (BioAnalyzer).
Genomic DNA isolated from matched cell sources were used as positive controls. (C)
Visual representation of the data shown in B. Black arrow indicates the largest
fragment size DNA, seen in cell samples; blue arrow indicates high molecular weight
(>2Kb) fragments; red arrow indicates 150bp nucleosome band. (D) Representative
NTA Nanosight plots for each isolation method, including ultracentrifugation, size
exclusion, optiPrep fractions 1-6, and optiPrep fractions 7-12. Plots indicate consistent
size distribution and provide particle concentrations for each sample. Samples were
diluted 1:100 in sterile water for measurement.
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Copy Number Analysis of Exosome DNA Across Different Isolation Methods
Whole genome sequencing was performed on the DNA isolated from
exosomes from each method, with or without Dnase treatment. Prior to Dnase
treatment, exosomal DNA fragments collected from each method, when pooled, cover
the entire genome with copy number variations (CNVs) closely matching those found
in matching cellular genomic DNA (Figure 10 A,B,C). However, after Dnase
treatment, only the size exclusion-generated exosomal DNA produced CNVs that still
matched the cellular DNA very closely. Yet, each sample still spanned the entire
genome and generally reflected the CNV patterns of the cells of origin (Figure 10
A,B,C). This data further suggests that size exclusion is the optimal exosome isolation
method for exosomal DNA applications.
Exosomal DNA is Degraded After Membrane Lysis
To ensure that the Dnase-resistant DNA was indeed able to be degraded after
losing the protection of the exosome membrane, we treated isolated DNA with Dnase
post-lysis. DNA was used from each exosome isolation method, as well as cellular
genomic DNA, and all were analyzed by capillary electrophoresis (BioAnalyzer). As
expected, the DNA was degraded when treated with Dnase post-lysis, but not prelysis of the exosome membrane (Figure 11). This supports the notion that the DNA is
intraluminal and is protected from degradation by being encapsulated within the
exosomal membrane, instead of having degradation prevented by some other
mechanism.
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Figure 10. Exosomal DNA fragments Cumulatively Cover the Whole Genome.
(A,B,C) Total exosomal DNA and Dnase-protected exosomal DNA were isolated from
three different cell lines using the three methods described previously. DNA from each
condition was subjected to whole genome sequencing and analyzed for copy number
variations in comparison with genomic DNA isolated from the cells of origin. Exosome
DNA isolated by size exclusion provides the best representation of copy number
patterns compared with genomic DNA, regardless of DNase pre-treatment. The copy
number patterns are shown for MDA-MB 231 (A), SW620 (B), and DiFi (C). Copy
number gains are illustrated in red, losses in green, and neutral sites are blue.

Figure 11. Exosomal DNA is degraded after membrane lysis.
DNA was isolated from SW620 cells and exosomes. Exosomes were isolated by
ultracentrifugation (UC), Size Exclusion (SE), and OptiPrep density gradient
fractionation. For each method, samples were either untreated, treated with Dnase
pre-lysis, or treated with Dnase post-lysis. In each case, treatment with Dnase postlysis degraded the large fragments of DNA while those fragments were preserved with
treatment pre-lysis.
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Western Blot Validation of Exosome Markers
To demonstrate the presence of exosomes in the appropriate fractions for size
exclusion and the optiPrep density gradients, western blots for canonical exosome
markers were run for the samples from each cell line. As observed previously for the
density gradients218, exosome markers CD63, CD81, and CD9 were predominantly
seen in fractions 2-6 (Figure 12 B,D,F) with flotation density between 0.4-1.18. For
size exclusion, the same markers co-localized as expected in the exosome-rich
fractions 7-10, while soluble proteins eluted in the non-overlapping distal fractions
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(Figure 12 C,E,G). Additionally, it is thought that extranuclear genomic DNA remains
associated with histones and, at least in part, retains nucleosome organization282.
Indeed, evidence of a band pattern consistent with approximately 150-bp nucleosome
structures is clearly visible in Figure 9C. In agreement with this, optiPrep density
gradient fractions showed an enrichment of histone 4, especially in the exosomes
released by MDA-MB-231 and DiFi cells (Fig 12 B,D,F). All size exclusion fractions
positive for CD63, CD81, and CD9 were also strongly positive for histone H4 (Figure
12 C,E,G). Finally, to ensure that the optiPrep fractions had in fact separated into
layers of increasing density from 1-12, absorbance was measured at 340nm
wavelength with a plate reader for every gradient, as described elsewhere278. A
representative plot of flotation density from one gradient is shown in Figure 12A.
Flow Cytometry Validation of Exosome Markers
As a secondary method of exosome validation, we took exosomes from each
isolation method, with and without DNase treatment, and assessed the samples for
the presence of the canonical exosome markers CD9 and CD81 via flow cytometry.
Exosomes were bound to aldehyde/sulfate beads (Invitrogen A37304) and incubated
with the appropriate primary antibody (Table 4). Secondary antibody (Alexa Fluor 488
donkey anti-mouse, Invitrogen A21202) was added and beads were subsequently run
on the BD LSR Fortessa flow cytometer for analysis. Exosomes isolated by each
method were highly positive for both markers, though the UC isolation samples were
not as positive as SEC or density gradient, consistent with the idea that UC is the
method with the lowest sample purity (Figure 13A,B). Additionally, this data serves to
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Figure 12. Western Blots for Exosome Markers.
(A) Flotation density plot for each optiPrep fraction as measured with a plate reader
at 340nm wavelength. The “light” or less dense fractions are indicated by the pale
background, while the heavy fractions have a red background. (B-G) Exosomes were
isolated by ultracentrifugation from three cell lines, MDA-MB 231, SW 620 and DiFi
and further purified by Iodixanol gradient ultracentrifugation (OptiPrep) and by size
exclusion chromatography (Sephadex columns, qEV, Izon). Fractions were run on
polyacrylamide gels and analyzed by western blots probed with antibodies for typical
exosomal markers, CD9, CD63 and CD81. To assess the potential distribution of DNA
among fractions, the membranes were also probed with antibodies for histone H4.
Note the overlap of histone H4 with tetraspanin-positive fractions.

Figure 13. Flow Cytometry Validation of Exosome Markers.
(A) Assessment of CD9 tetraspanin expression by flow cytometry. Exosomes from
each of the three isolation methods (UC, SE, Density Gradient) with or without DNase
treatment prior to lysis were bound to beads and stained for CD9. Unstained cells and
isotype controls were used for gating. The blue peak indicates CD9 expression in
comparison to the red isotype negative control. All samples tested were positive for
CD9, though the UC samples were the least positive (peak shifted left). (B)
Assessment of CD81 tetraspanin expression by flow cytometry. Results same as for
A, just with the CD81 marker, showing consistency in exosome marker expression
across all samples.
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confirm that even after DNase treatment, exosome surface markers remain intact,
indicating that they retain membrane integrity.
Argonaute-2 is also associated with exosomes across different isolation methods
Previous studies in our lab and others showed cell-autonomous miRNAprocessing capacity of exosomes, due to the presence of intraluminal Argonaute-2
(Ago-2) and other components of RISC complexes, such as Dicer30,283. These findings
were also questioned in the recent Jeppesen study, which identified Ago-2 in the nonEV fractions of isopycnic Iodixanol gradients218. Rigorous analysis of the exosomes
released by the same cell lines used in the paper showed, that, like DNA uptake, the
association of Ago-2 with the exosomes appeared to be at least partially cell-type
dependent. After crude exosomes isolated from DiFi cells were separated by Iodixanol
gradient, the exosomes were found in fractions 3-6, as was evidenced by WES of
fraction aliquots for the exosome marker Flotillin-1 (Figure 14A). Ago-2 was clearly
present in fractions 3-5 and formed a distinct secondary peak in fractions 7,8 (nonexosome-containing fractions) (Figure 14A). In the case of MDA-MB 231, the
exosomes were predominant in fractions 4-8. Ago-2 was significantly more abundant
than in DiFi exosomes and segregated in fractions 6-8 and 9-10 (secondary peak,
Figure 14B). Size exclusion eluates (fractions 7-10 and every 5th fraction thereafter)
presented with Ago-2 in all exosome-containing fractions (Figure 14C, D), but only in
the case of the DiFi cells were Ago-2 levels sufficiently high to detect a secondary
peak in a soluble fraction (fraction 20, Figure 14C).
To specifically determine the localization of Ago-2 relative to the exosome
membrane, we performed limited proteinase K digestion of crude exosome
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preparations as well as exosomes purified by size exclusion chromatography. As a
positive control, we used antibodies raised against the large extracellular loop of CD81
(aa 90-200), and antibodies against intraluminal protein Flotillin-1 served as a negative
control. The conditions were adjusted so that CD81 was completely digested, while
Flotillin remained intact (Figure 14E). Using the WES microcapillary immunoassay,
we showed that after proteinase K digestion, Flotillin-1 and a significant portion of Ago2 remained intact, while the extramembrane portion of CD81 was no longer detectable
(Figure 14F). Interestingly, another protein thought to be associated with exosomes,
an autophagy marker LC-3B, was clearly present in crude exosome preparations
(Figure 14G). However, it was readily removed by proteinase K digestion and not
detectable in the size exclusion-purified exosomes, suggesting that at least in this
biological context, exosome formation was independent of autophagy.
Conclusion
Here, we have definitively demonstrated the presence of DNA in exosomes
using multiple isolation methods, both with and without Dnase treatment. The amount
of DNA packaged within exosomes is highly variable depending on the cell line of
origin, but cumulatively recapitulates the entire genome. Additionally, exosomes
maintain surface marker integrity regardless of Dnase treatment, indicating their
membranes are intact. Exosomes also contain proteins such as tetraspanins CD63,
CD9, and CD81, as well as Histone H4 and Ago-2.
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Figure 14. Argonaute-2 is present in size exclusion and density gradient isolated
exosomes.
(A,B) Exosome fractions were isolated by optiPrep density gradient from the cell lines
DiFi (A) and MDA-MB 231 (B). Protein extracts were prepared and assessed for Ago2 content by WES microcapillary immunoassay. Similarly loaded extracts were probed
with antibodies for Flotillin-1 as a control to assess protein loading. Differences are
observed in Ago-2 incorporation between individual cell lines. (C, D) Crude Exosome
isolates were fractionated by size exclusion chromatography for the indicated cell
lines. Equal volume from each fraction was loaded onto a WES cassette and probed
with antibodies against Flotillin-1 (C), or Ago-2 (D) to assess exosome protein content.
Ago-2 was present in flotillin-positive fractions containing exosomes. (E) Proteinase k
treatment was optimized to completely degrade exosome membrane marker CD81,
representative

of

external

exosome-associated

proteins,

but

not

flotillin-1,

representative of intraluminal exosome proteins. (F) Proteinase k treated exosomes
from the indicated cell lines and isolation methods demonstrated a decrease in Ago2 but still clearly showed some remaining, indicating that at least a portion of the Ago2 associated with exosomes is inside the intraluminal space. (G) The autophagy
marker LC-3B is present in ultracentrifugation but not size exclusion-isolated
exosomes, and is degraded by proteinase k treatment. This suggests that LC-3B is
not contained within these exosomes, indicating they were generated in a process
independent of autophagy. These experiments were performed in collaboration with
Laura M. Snowden and Olga Volpert.
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CHAPTER 4
EXOSOME DNA METHYLATION
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Introduction
Despite the relative paucity of characterization of exosomal DNA compared to
other exosome cargo, several studies point to the great potential of exosomal DNA as
a biomarker for diagnosis and monitoring of cancer and other diseases. Indeed,
multiple groups have been able to isolate exosomal DNA from patient samples and
identify specific polymorphisms and pathogenic mutations in those specimens
107,162

105–

. There has been very little investigation, however, into determining whether or

not epigenetic modifications can be detected on exosomal DNA and if so, whether
they are representative of the state of the donor epigenome. Studies over the past
several decades have made it increasingly obvious that mutations alone do not
comprehensively define many complex disease states, such as cancer284. Epigenetic
profiles, especially methylation patterns, have also been demonstrated to provide
valuable clues for the diagnosis and treatment of disease, as methylation changes
can be as effective as mutations in disease pathogenesis285,286. It has now been well
established that differential methylation can produce clinically relevant changes in
gene expression, with major roles in the development and outcome of several
diseases287. Thus, developing new methods for the detection of aberrant methylation
profiles or patterns, especially those linked to disease progression, would be
invaluable.
Perhaps because the field of exosomal DNA research is relatively nascent,
there is a distinct lack of information with regards to exosomal DNA methylation. The
existing epigenetics-related exosome studies have instead focused on the ability of
exosomes to perpetrate epigenetic changes in recipient cells by delivering protein
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cargo capable of enhancing methylation or demethylation 288. To date, the number of
published studies analyzing the potential of exosomal DNA for methylation detection
remains minimal. In the first study, done by the Lyden group, a DNA dot blot probed
for anti 5’-methyl cytosine and demonstrated comparable levels of methylation on
cytosines in exosomal DNA and in cellular genomic DNA47. Another group interested
in gastric cancer demonstrated similar methylation profiles of the BARHL2 locus,
LINE1, and SOX17 genes in the exosomal DNA from the gastric juice and gastric
cancer cells of patients by site-specific bisulfite PCR and bisulfite pyrosequencing289.
Beyond these studies, no comprehensive analysis have been performed investigating
the extent, patterning or potential function of exosomal DNA methylation. We
hypothesized that exosomal DNA is methylated, and that the methylation patterns on
exosomal DNA recapitulate those of the cell of origin. The aim of this section is to
systematically address the correlation between methylation patterns in the exosomal
DNA and cells of origin. These findings will provide solid foundation for potential use
of exosomal DNA methylation analysis as a diagnostic strategy. This is especially
relevant for cancers notorious for late diagnosis, such as pancreatic ductal
adenocarcinoma (PDAC).
Characterization of PDAC Cell Line Exosome DNA Methylation
Exosomal DNA is Methylated
Initial experiments aimed to determine whether exosomal DNA is methylated
(Figure 15). For that purpose, genomic DNA was isolated from cells and matched
exosomal DNA were collected by ultracentrifugation. Six tumorigenic PDAC lines
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(Panc1, BXPC3, Capan-1, T3M4, MiaPaCa2, and PSN1) and two non-tumorigenic
lines (HPNE and HPDE) were used. The DNA was then purified using the method

Figure 15. Schematic of methylation detection experiment design
Nuclear genomic and exosomal DNA were isolated from multiple cell lines, both
tumorigenic and non-tumorigenic, and subsequently underwent bisulfite conversion,
library formation, and reduced representation bisulfite sequencing (RRBS).

described previously (DNeasy Mini Kit, Qiagen with minor modifications) and
subjected to bisulfite conversion, a process that changes unmethylated cytosines into
uracils, which are subsequently converted to thymidines during PCR amplification.
This method allows for the identification of methylated and unmethylated cytosines
when sequenced. Samples then underwent reduced representation bisulfite
sequencing (RRBS). While genome-wide cytosine methylation analysis is possible,
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methylated cytosines tend to cluster in CpG dinucleotide-rich areas called CpG
islands, often in the promoter regions of genes, that collectively span a very small
portion of the genome. RRBS targets CpG rich regions using a primer library, which
then generates site-specific fragments. This method also only requires small amounts
of DNA, which is useful for exosomal DNA applications290,291. During analysis, the
amplified fragments, or reads, are mapped to specific regions of DNA using reference
sequences. The number of C-to-T conversions is then quantified for all of the mapped
reads, generating a beta value for methylation at each site. Samples can then be
compared in a site-specific manner between conditions, in this case between
exosomal and matched cellular DNA.
A custom bioinformatics analysis pipeline was generated for this application
through a collaboration with Dr. Kunal Rai’s laboratory at MD Anderson Cancer
Center. Analysis of the first cell line tested, Panc1, demonstrated site-specific
methylation patterns for both the exosome and cellular nuclear DNA. A Pearson
correlation coefficient was calculated and exosome DNA methylation was observed
to be highly concordant with the nuclear DNA methylation (Figure 16). Interestingly,
when differences were observed, exosomal DNA was more often hypermethylated
(n=3510 genes) than hypomethylated (n=27 genes) compared to the nuclear DNA,
suggesting that perhaps exosomal DNA is protected from demethylating enzymes
when it is packaged inside exosomes. Subsequently, the analysis was expanded to
include multiple cell lines, and the quality control of sequencing data showed sufficient
quality, read depth, and alignment to produce reliable results (Figure 17 A-C).
Therefore, we for the first time provide conclusive reliable and reproducible evidence
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Figure 16. High correlation between cell and exosome methylation patterns.
Correlation of methylation patterns between cell gDNA end exosome DNA isolates
was very high, with a Pearson Correlation coefficient of 0.94. These samples are
representative of what was observed across multiple cell lines. Exosome samples
were treated with Dnase prior to lysis. This analysis was performed by Dr. Tommy
Tang in Dr. Kunal Rai’s laboratory.
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Figure 17. Quality control of sequencing data
(A) Alignment rates were high among all samples. (B) base call quality is high,
indicating there are few sequencing errors and the reads can be accurately analyzed.
(C) There is a high number of duplicates, which is expected as a result of the primer
library used in RRBS to amplify specific sites of the genome.

that exosomal DNA is methylated and harbors highly conserved methylation patterns
from the cell of origin.
Exosome DNA Methylation Patterns Reflect Methylation of the Cell of Origin
We then aimed to determine whether the methylation patterns seen in the
pooled exosome samples were sufficiently unique to provide a cell line-specific
signature. To achieve this, broad Pearson Correlation analyses were performed to
compare each cell and exosome sample from a given cell line to those from others
(all done in biological triplicates, 6 samples total per line, 3 cell and 3 exosome). As
illustrated in Figure 18, methylation patterns identified on cell gDNA and exosomal
DNA are closely matched when compared within a single cell type. However, if
samples are compared between cell lines, the correlation significantly decreases.
These data suggest that exosomal DNA not only recapitulates the methylation
patterns of the cell of origin but also carries a cell-specific methylation signature with
high fidelity.
Exosome DNA Methylation Patterns Can Specifically Identify the Cell of Origin
Since we discovered that methylation patterns found on exosomal DNA are
distinct and correlated extremely well with the methylation patterns observed on the
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Figure 18. There is high methylation pattern correlation among samples from
the same cell line. Example of a comparison between genomic cell and exosome
DNA for two lines, Panc1 and HPDE. As outlined in red, samples from the same cell
type, regardless of origin, cluster together. Samples from different cell lines have
markedly lower correlation. This analysis was performed by Dr. Tommy Tang in Dr.
Kunal Rai’s laboratory.
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Figure 19. Clustering Analysis for All Eight Cell Lines.
All biological replicates of cellular and exosomal DNA from each individual cell line
cluster together, based on methylation pattern comparison. The segregation of
exosome and nuclear DNA according to the cell line of origin indicates that exosomal
DNA carries a cell line-specific signature. This analysis was performed by Dr. Tommy
Tang in Dr. Kunal Rai’s laboratory.
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genomic DNA of the cell of origin, we then performed a clustering analysis across all
cell and exosome samples. (Figure 19). This assay demonstrated that both the
cellular gDNA and exosomal DNA from each individual cell line cluster together, and
are unique and separate from any other line. This implies that exosome-derived
methylation signatures could be used for the detection of cancer-specific markers in
patients.
Methylation Marks Detected on Exosome DNA Span All Chromosomes
Since RRBS employs sequencing library generation using primers specific to
known frequently methylated areas of the genome, it is possible to perform a postsequencing analysis of genome read coverage. We demonstrate here that exosomal
DNA methylation patterns are representative of every chromosome in the genome in
every sample. This finding provides conclusive evidence that pooled exosomal DNA
preparations can yield genome-wide methylation data, with no overt biases for any
specific loci or hotspots (Figure 20).
Exosome DNA Can be Used to Investigate Site-Specific Methylation Changes
We next tested the possibility of probing the exosomal RRBS sequencing
datasets for the presence of cancer-specific methylation changes when comparing the
PDAC and non-tumorigenic cell lines. An in-depth literature search identified over 75
functionally diverse genes differentially methylated in PDAC (Table 7). The top six
were chosen for site-specific analysis (Table 8). The Broad Institute Integrative
Genomics Viewer (IGV) software was used to visualize methylation levels in the
promoter regions of the genes of interest (Figure 21A). The percentage of methylated
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Figure 20. Methylation marks from cells and exosomes span all chromosomes.
Representative analysis of reads per chromosome for each sample (3 cellular
genomic and 3 exosome DNA samples for each cell line, 8 cell lines total). Each plot
represents a single sample, and each gray bar indicates a single chromosome. Every
chromosome is represented in every sample. This analysis was performed by Dr.
Tommy Tang in Dr. Kunal Rai’s laboratory.
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Table 7. Genes Differentially Methylated in PDAC.
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Table 7 Continued.

Table References289,292–298
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reads was determined on a single-base pair level, for all CpG dinucleotides within the
promoter regions (Figure 21B). For the six genes of interest, the average overall
promoter methylation was determined for both the genomic and exosomal DNA
samples from all eight cell lines used in the study (Figure 22). Similar methylation
patterns were maintained in exosomal/cellular gDNA in tumorigenic and nontumorigenic groups, with the non-tumorigenic lines generally demonstrating promoter
hypomethylation

and

the

tumorigenic

lines

presenting

with

promoter

hypermethylation, consistent with published information for each of the gene
methylation states (PDAC vs. healthy tissue). There is some variation within the
groups on a cell-line specific basis, which is to be expected due to variability due to
inherent cell culture heterogeneity. These findings indicate that exosomal DNA can
be utilized to identify site-specific methylation changes with good reliability, which
could be utilized for discovery or precision medicine.
Exosome DNA Can Detect Decreased Methylation in Cells Treated With 5AZA
Since demethylating agents are being utilized in cancer therapy299, we chose
to investigate whether exosomal DNA is suitable for the detection of large-scale
methylation changes resulting from treatment with 5-Azacitidine (5AZA), a chemical
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Figure 21. Use of Broad IGV Software to assess site-specific methylation.
(A) Visualization of methylation (blue bars) in the promoter region (red box) of the
gene ELOVL4 across cellular and exosomal DNA samples. This strategy allows for
quantification of methylation in specific regions of genes of interest. (B) Methylation
rates of individual CpG dinucleotide sites shown as percentage of methylated reads
at each site in each sample. Allows for an assessment of the degree of methylation at
each site in a given sample.

Figure 22. Average Overall Promoter Methylation in Genes Frequently
Hypermethylated in PDAC.
(A-F) Six genes established as frequently hypermethylated in pancreatic cancer
(ELOVL4 (A), BNIP3 (B), ZNF415 (C), TFPI2 (D), RASSF1A(E) and CLDN5 (F)) were
assessed for percentage of promoter methylation levels in both cellular genomic and
exosome DNA samples. Non-tumorigenic cell lines (HPNE, HPDE) are shown on the
left and tumorigenic ones (Panc1, T3M4, BXPC3, MiaPaCa2, Capan1, PSN1) are on
the right in each graph. Generally, the non-tumorigenic samples from both genomic
and exosomal DNA exhibited hypomethylation while tumorigenic samples showed
hypermethylation, consistent with PDAC methylation changes reported in the
literature.
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analogue of the nucleoside cytidine that, at low doses, inhibits DNA methyltransferase
and causes DNA hypomethylation300. Panc1 cells were treated with increasing doses
of 5AZA to generate a dose-response curve and determine the optimal non-lethal
demethylating dose (Figure 23A). We then utilized this dose in a high- sensitivity
fluorescence-based assay to detect methylated DNA using a 5-methylcytosine
antibody in Panc1 nuclear gDNA and exosome DNA from cells with and without
exposure to 5AZA. Preliminary experiments have shown that decreased methylation
levels could be detected in exosomes isolated from 5AZA-treated cells (Figure 23B).
This highlights a potential application for using patient-derived exosomes to monitor
the in vivo efficacy of demethylating agents.

Figure 23. Exosomes can be used to detect drug-induced methylation changes.
(A) Dose-response curve to determine the optimal non-toxic dose of 5-AZA in Panc1
cells (red box). (B) Methylation levels were assessed in nuclear genomic DNA and
exosomal DNA from cells with or without 5AZA treatment using the Abnova
Methylated DNA Quantification Kit. Formulas for methylation level calculations are
shown. Methylation levels are decreased in both genomic and exosomal DNA
samples after 5AZA treatment, indicating that exosomal DNA reflects rapid
methylation changes due to drug treatment.
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Analysis of Exosomal DNA Methylation in PDAC Patients
PDAC Patient Information
In current work, we have begun to evaluate the utility of exosomes for clinical
analysis of DNA methylation. We obtained three matched PDAC patient tumor - serum
pairs in order to perform a comparison between methylation patterns. This is a
significant challenge since only a fraction of exosomes in the patient’s circulation
originates from the tumor, while other exosomes come from non-cancerous tissues
and are likely to have distinct methylation patterns. Thus, it is unclear whether the
sensitivity of this method will be sufficient to discern cancer-derived epigenetic
signature(s). Patient information is shown in Table 9. All patients had a confirmed
PDAC diagnosis and underwent a type of tumor resection surgery. We obtained snapfrozen fragments of resected tumor and serum from each patient.

Differences in Exosome Sequencing Preparation Using Serum Exosomes
DNA was isolated directly from tumor tissue for analysis. For the matched
serum samples, a modified exosome isolation procedure via ultracentrifugation was
employed using an extended spin time to maximize exosome yield from small-volume
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samples. Exosomal DNA yield varied widely between patients, necessitating
additional ultracentrifugation of the retained supernatants. Additionally, the DNA
isolation protocol was modified, by extending elution procedure from the purification
columns for several hours to maximize DNA yields. We elected to perform whole
genome bisulfite sequencing (WGBS) instead of RRBS for these samples, due to the
lower quality and increased fragmentation of the serum exosome DNA. WGBS does
not require site-specific library generation and thus is not hindered by increased
fragmentation. A major limitation for methylation-based sequencing analyses is the
requirement for sufficient amounts of template DNA for bisulfite conversion prior to
sequencing, with large enough fragments for library preparation in case of RRBS. We
found that a minimum of 200ng of exosome DNA is required for RRBS/WGBS to be
successful, and given the heterogeneity of serum exosomal DNA additional sample is
preferable in order to generate sufficient read depth. A schematic of the isolation
workflow is presented in Figure 24.

Figure 24. Schematic of patient sample isolation methods.
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Currently, we have completed bisulfite conversion, library generation, and
sequencing for three matched sets of patient samples (tumor and serum exosome
DNA). Obstacles for analysis have included high noise and low base read coverage,
likely due to the presence of non-tumor exosomes in the patient serum, a confounding
variable not present when isolating exosomes from purified cell line populations.
Strategies for optimization may include utilizing a higher volume of input serum for
exosome isolation or targeted sequence amplification for relevant site-specific
oncogenic methylation changes.
Conclusion
Exosomal DNA is methylated, and as shown above can faithfully recapitulate
the methylation patterns of the cell of origin with high fidelity. Additionally, the
exosomal DNA methylation marks collectively span the entire genome and can be
sequenced and mapped for the analysis of genes of interest. Exosomal DNA
methylation patterns can be used to detect site-specific changes in methylation, and
can potentially identify oncogenic changes in cancer patients using biological fluid
liquid biopsies.
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CHAPTER 5
EXOSOME DNA PACKAGING
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Introduction
One of the major unanswered questions concerning exosomal DNA is the
mechanism of DNA packaging into exosomes. Thus far, while several theories have
been put forward, no studies have demonstrated how, or in what contexts, DNA is
incorporated into exosomes. It is plausible that the mechanisms enabling the
packaging of DNA into exosomes could be cell-type specific and dynamically
regulated. While early studies suggested that exosomal DNA may be a characteristic
of cancer cells and not of non-tumorigenic cells47, data presented earlier in this work
clearly shows that both tumorigenic and non-tumorigenic lines are capable of
producing large amounts of exosomal DNA. The levels of exosomal DNA are however
widely variable between different cell lines regardless of tumorigenicity. It has been
proposed that exosomal DNA could escape into the cytoplasm at times when the
nuclear envelope is compromised or, in the case of mitosis, disassembled276. The
biogenesis of exosomes involves the formation of multi-vesicular bodies of endosomal
origin, which could potentially draw in cytoplasmic components during intraluminal
membrane budding, to be encapsulated within exosomes40. If DNA, either free or
organized in nucleosomes, was present in the cytoplasm, this could be one
mechanism by which it could appear in exosomes. Indeed, a recent study by
Takahashi et al. proposed that exosomes maintain cellular homeostasis by removing
cytosolic DNA from cells, keeping DNA fragments from being sensed by STING and
thereby preventing the activation of harmful innate immune responses and reactive
oxygen species (ROS)-driven DNA damage responses108.
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The mechanism by which DNA could escape the nucleus, however, remains
elusive. A family of proteins have been shown to be frequently disrupted in cancer
cells with potential consequences for the integrity of the nuclear envelope. Altered or
aberrant expression of the Lamin proteins, specifically Lamins A & C, have been
commonly observed to be disrupted in cancer cells, leading to nuclear envelope
disruption and other effects that can promote tumor progression301–303. Lamins have
also been ascribed a role in chromosomal organization and movement during different
phases of the cell cycle; this role indicates interactions with DNA304. We decided to
investigate the hypothesis that exosomal DNA packaging is dependent on nuclear
envelope integrity. Here, we sought to determine whether manipulating nuclear
envelope integrity by altering Lamin A/C expression could influence exosomal DNA
content by increasing the permeability of the nuclear membrane and increasing DNA
mobility by reducing lamin-mediated anchorage. This could provide important
mechanistic insight for exosomal DNA packaging by linking exosomal DNA content to
the structural integrity and permeability of the nucleus.
Linking Nuclear Envelope Integrity and Exosome DNA Content
Demonstration of Lamin A/C Knockdown in Cells
Lamin A/C knockdown has been demonstrated to be non-lethal to cells, due in
part to the functional redundancy of Lamin B305,306. We performed an siRNA
knockdown of Lamin A/C in three cell lines, Panc1, T3M4, and HPNE. The lines were
chosen based on their tumorigenicity and exosomal DNA packaging capabilities.
Panc1 is tumorigenic, with low baseline DNA content, T3M4 is tumorigenic with high
baseline DNA content, and HPNE is non-tumorigenic with very low amounts of
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detectable exosomal DNA. Knockdown efficiency in each cell line was validated by
qPCR expression analysis (Figure 25A).
Exosome DNA Content Correlates With Lamin A/C Expression
After confirming the siRNA knockdown of Lamin A/C in the cells of interest, I
proceeded to isolate exosomes from control (untreated, transfection agent alone,
scrambled siRNA control), and Lamin A/C knockdown cells. The same number of cells
were seeded for each condition and grown to 75-85% confluence prior to exosome
collection. DNA was then isolated from exosomes as described previously. For each
cell line, Lamin A/C knockdown caused a dramatic increase in exosomal DNA content,
which was statistically significant (Figure 25B). This work implies a link between
exosomal DNA packaging and the integrity of the nuclear envelope.
Conclusion
Here, we demonstrate that by decreasing the expression of the nuclear
envelope structural proteins Lamin A & C a corresponding increase in exosomal DNA
was observed. This implies that nuclear envelope breakdown or compromise could be
an integral part of the process of packaging DNA into exosomes. While further work
is necessary to characterize the mechanism by which this occurs, this implicates both
normal (cell cycle mediated nuclear envelope breakdown) and pathological (Lamin
expression dysregulation) processes in exosomal DNA packaging.
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Figure 25. Lamin A/C Knockdown significantly increases exosomal DNA
content.
(A) Lamin A/C siRNA knockdown validation by qPCR expression assay. (B) Exosomal
DNA content is significantly upregulated after Lamin A/C knockdown in all three cell
lines tested (Panc1, T3M4, and HPNE) when compared with untreated, transfection
reagent, and siRNA scramble control conditions. Only one T225 flask of subconfluent
cells per condition was used, as compared with the initial exosomal DNA
characterization experiments where 3 flasks per line were used.
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CHAPTER 6
EXOSOMES AS DNA DAMAGE RESPONSE MEDIATORS
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Introduction
Increasing evidence suggests that exosomes are critical for cell-cell and crosstissue communication under both normal physiological conditions and in cancer by
shuttling variegated cargo, including DNA, RNA, and proteins, between cells16,84,202.
Exosome-mediated signaling has been implicated in a variety of functions such as
angiogenesis, immunity, proliferation, and tumorigenesis40,65,152,307. Since exosomes
are released from virtually all cell types, and because their cargo has been shown to
vary based on microenvironmental context such as cytotoxic stress, it is likely that
their roles are context dependent and are influenced by environmental factors308.
Chemotherapy and radiation eliminate cancer cells by causing acute genotoxic
stress due to massive, genome-wide DNA damage. An unintended consequence of
these treatments is the transfer of DNA damage response (DDR) from cancer cells to
non-cancerous cells nearby309. Termed the bystander effect, this induction of DDR
signals has been characterized in cells that have not been directly subjected to DNA
damage but exist in proximity to irradiated cells 310,311. The bystander effect can have
deleterious functional consequences, including DNA damage, chromosomal
instability, mutations, and apoptosis309,312. While some molecular mediators of the
bystander effect have been established, including reactive oxygen species
(ROS)313,314, other mechanisms remain unclear. Additionally, almost all studies of the
bystander effect focus on radiation-mediated damage, while little is known regarding
the bystander effect of soluble damaging agents like chemotherapy. Some studies
have suggested soluble factors such as cytokines could play a role312,315.
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Given the well-established roles of exosomes in intercellular signaling, several
groups have proposed exosomes as mediators of the bystander DDR effect. Some
studies have shown that exosomes derived from irradiated cells show characteristic
changes in cargo, including protein and RNA species, that could lead to downstream
effects in naïve cells316–318. Additionally, it has been demonstrated that exosomes can
induce bystander responses in naïve cells, potentially related to the transport of ROS
or RNA molecules319–321. Overall, however, the mechanisms by which exosomes can
generate bystander responses in cells remain vague and undefined. We hypothesize
that exosomes mediate paracrine bystander DNA damage responses via the
transportation of signaling molecules from cancer cells to naïve recipient cells. Here,
we propose a role and a potential mechanism for exosomes in mediating paracrine
DNA damage response activation in treatment-naïve, undamaged cells (Figure 26).

Figure 26. Proposed model of exosome-mediated paracrine DDR activation.
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Effects of DNA Damage on Exosomes
DNA Damage Increases Exosome Release
Initially, we decided to characterize some of the properties of exosomes in
the context DNA damage using different agents, hydrogen peroxide (H2O2) and
ultraviolet (UV) radiation. H2O2 is a soluble factor that is converted into ROS and
generates genome-wide double strand breaks, while UV radiation is a non-soluble
DNA-damaging agent that causes the formation of T-T and T-C dimers, subsequently
resulting in single and double-strand breaks
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. We first assessed exosome release

in the context of DNA damage in three different PDAC cell lines (Panc1, T3M4, HPNE)
and normalized the particle concentration to cell number. We found that while these
two DNA-damaging agents did elicit a moderate increase in exosome release across
all cell lines, the increase was not significant in comparison with control untreated cells
(Figure 27A). One caveat to this approach is that the doses of response agents used
were optimized specifically to be non-lethal, to enable cell survival for exosome
collection, so a dose-response curve may be able to discern whether more toxic, and
therefore more stressful, doses of each agent generate more exosomes.
DNA Damage Does Not Impact Exosome Size
We also assessed the average size of the exosomes released by the same
three cell lines, under the same conditions. Using Nanoparticle Tracking Analysis
(Nanosight) we were able to determine that the size of exosomes is not impacted by
DNA damaging agents. In fact, exosomes from each cell line in each condition had
remarkably uniform size profiles (Figure 27B).
DNA Damage Rarely Impacts Exosome DNA Content
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Initially, we hypothesized that DNA damaging agents might generate an
increased number of cytoplasmic DNA fragments that would be packaged into
exosomes, leading to higher levels of DNA in exosomes released by the cells
subjected to DNA damage. In this case, large amounts of fragmented exosomal DNA
delivered to recipient cells could be the cause of bystander DDR by activating ectopic
DNA sensing molecules in the cytosol, such as STING and Toll-Like Receptors
(TLRs)108,323,324. However, when we measured DNA in the exosomes released from
cells treated with DNA damaging agents, we found very modest upregulation of
exosome DNA levels (Figure 27C). There was one notable exception; when T3M4
cells were subjected to UV radiation (but not H2O2) their exosomal DNA content was
increased more than 10-fold compared to all other conditions. This finding again
indicates that packaging and sorting of exosomal contents is cell line and context
dependent.

Figure 27. Effects of DNA damage on exosome properties.
(A) Treatment with either soluble (H2O2) or non-soluble (UV) DNA damaging agents
modestly increased exosome release in three different cell lines (Panc1, T3M4,
HPNE), however none of the differences were statistically significant. (B) DNA
damage induction did not change the size of exosomes released by cells, as
measured by Nanosight NTA. (C) DNA damaging agents did not significantly increase
exosomal DNA levels, with the exception of UV-damaged T3M4 cells, which showed
a dramatic increase in exosomal DNA content after treatment,
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Exosomes from cells treated with DNA damaging agents Elicit Paracrine DNA
Damage Responses in Naïve Cells
Exosomes from PDAC Cells with Induced Damage Activate DDR In Naïve Cells.
After establishing that treatment of cells with DNA damaging agents did not
appreciably alter exosomal DNA content, with the exception of UV-treated T3M4 cells,
we tested exosomes exosomes from identically treated cells for the ability to elicit a
DNA damage response in naïve (untreated) cells. We chose to incubate naïve cells
with exosomes from the two cancer cell lines, Panc1 and T3M4, that had been
exposed either to a soluble (H2O2) or non-soluble (UV) DNA damaging agent. We
tested four conditions, untreated negative control, exosomes from naïve (untreated)
cells, treatment with exosomes from cells following DNA damage, and cells treated
directly with the DNA damaging agent of choice (positive control). At the end of
treatment, the cells were stained with EdU to visualize actively replicating cells in SPhase, when homologous repair of DNA double-strand breaks occurs, and p-gH2AX
as an indicator of DNA damage response. Nuclei were visualized with the DNA
intercalating dye DAPI. We utilized non-malignant pancreatic epithelial cells HPDE as
recipient cells, in order to partially recapitulate the balance between cancer cells as
donors and normal stroma as recipients of exosomes in the tumor microenvironment.
A schematic of the experimental design is shown in Figure 28.
Interestingly, when we incubated the treatment-naïve cells with exosomes from
the cancer cells exposed to DNA damage, we saw a significant upregulation in pgH2AX signal, suggestive of DNA damage response. We did not observe a significant
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Figure 28. Schematic of DNA damage response experimental design.

Figure 29. Exosomes from damaged cancer cells generate activated DDR in
treatment-naïve recipient cells.
(A) Staining images of HPDE cells. conditions are untreated negative control,
incubated with exosomes from undamaged Panc1 cells, exosomes from H2O2damaged Panc1 cells, and positive control H2O2 treatment. DNA damage is indicated
by the red p-gH2AX-positive cells, while replicating cells are the green EdU-positive
cells. (B) Same as A but with T3M4 exosomes. (C) Same as A but with UV as the
damaging agent. (D) Same as B but with UV as the damaging agent. Scale bar 20µm.
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increase in the cells incubated with exosomes from undamaged cancer cells (Figure
29A-D). To further analyze this phenomenon, we generated a dose-response by
testing increasing concentrations of exosomes for the treatment of naïve cells (2
billion, 10 billion, or 50 billion per condition).We observed a dose-dependent increase
in cells positive for p-gH2AX with increasing exosome concentration, demonstrating
that the induction of DDR in the recipient cells was exosome mediated (Figure 30AD). The increase in DDR activation signal was observed with exosomes from both
Panc1 and T3M4 cells of origin, treated with either H2O2 or UV.
Exosomes from Non-Malignant Cell Lines subjected to DNA Damage Do Not Activate
DDR in Naïve Cells
Next, we wanted to investigate whether the induction of paracrine DDR
activation was specific to exosomes from cancer cells. We induced DNA damage
using the UV and H2O2 in two non-malignant cell lines, BJ fibroblasts and HPNE
pancreatic epithelial cells. Exosomes were isolated and experiments performed
following the same experimental design as above, and we assessed DNA damage
activation in the same recipient HPDE cells by percentage of p-gH2AX positive cells.
Strikingly, we saw that the exosomes from non-malignant cells failed to induce
paracrine DDR in the naïve recipient cells, despite the exposure of the exosome donor
cells to DNA damaging agents that were shown to induce DDR (p-gH2AX positivity) in
positive control cells (Figure 31). This effect was even more apparent when dose
response was evaluated and no induction of paracrine DDR was observed with up to
5x1010 exosomes (Figure 32 A-D).
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Figure 30. Exosomes from damaged cancer cells increases activation of DDR in
recipient cells.
(A) Dose response of HPDE cells to exosomes from Panc1 treated with H2O2.
Between 2 and 50 billion exosomes were used. Data are expressed as % p-gH2AX
positive cells (a marker of DDR activation). There was no significant increase in DDR
activation when HPDE cells were incubated with 10 billion exosomes from untreated
cells. HPDE cells treated directly with H2O2 were used as a positive control. (B)
Identical experiment was performed using exosomes from Panc-1 cells treated with
UV. Positive control – UV-irradiated HPDE cells. (C,D) Identical experiments were
performed using T3M4 cells for exosome collection.
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Exosomes from Treatment-Naïve Cells Do Not Induce DDR
We then sought to determine whether exosomes isolated from naïve cancer
and non-malignant cells would induce a DDR if applied at higher concentrations.
Exosomes were isolated from the same cell lines (Panc1, T3M4, BJ, HPNE), and used
to treat HPDE recipient cells at increasing concentrations to assess potential dose
response (Figure 33; 34A-D). However, we were unable to detect DDR induction
upon treatment with exosomes from naïve cells, regardless of exosome
number used. These findings suggest that the induction of the paracrine DDR was
specific only to exosomes released by cancer cells undergoing genotoxic stress.

Figure 31. Exosomes from non-tumorigenic cells do not induce paracrine DDR
activation in recipient cells.
Staining images of HPDE cells. conditions are untreated negative control, incubated
with exosomes from undamaged non-tumorigenic HPNE cells, exosomes from H2O2damaged HPNE cells, and positive control H2O2 treatment. DNA damage is indicated
by the red p-gH2AX-positive cells, while replicating cells are the green EdU-positive
cells. No significant increase in DDR was observed in either of the exosome
conditions. Scale bar 20µm.
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Figure 32. Exosomes from damaged non-tumorigenic cells do not increase
activation of DDR in recipient cells.
(A) Dose response of HPDE recipient cells to exosomes from H2O2-treated HPNE
cells, shown as % p-gH2AX positive cells. Note the lack of increase in DDR upon
treatment and apparent increase in the positive control (H2O2). (B) Same as A, with
UV as the DNA damaging agent. Positive control, UV-treated HPDE cells. (C, D)
Experimental design as in A, B using BJ fibroblasts as the exosome donor cells. Scale
bar 20µm
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Exosome-induced DDR is independent of Recipient Cell Type
To this point, we had consistently utilized HPDE as the recipient cell line for
exosome-induced DDR assessment. To determine if the effect was restricted to HPDE
cells, we performed similar experiments using Panc1 cells as exosome recipients, to
ascertain whether exosome-induced activated DDR could be elicited in cancer cells
as well as non-tumorigenic epithelial cells. Additionally, we wanted to determine
whether exosomes could induce a positive feedback loop by propagating DDR in
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Figure 33. Exosomes from undamaged cells do not induce DDR.
HPDE cells were incubated with increasing concentrations of untreated HPNE cell
exosomes. No induction of DNA damage response was observed in the recipient cells
regardless of exosome concentration (red signal, p-gH2AX positive cells). Similar
results were seen regardless of exosome donor cell line. Scale bar 20µm.

unaffected cells. We repeated the experimental strategies outlined above using naïve
untreated Panc1 cells as exosome recipients with nearly identical results, wherein
exosomes from cancer cells undergoing DNA damage had the capacity to propagate
DDR in the naïve cells, while exosomes from naïve cancer cells and all nontumorigenic cells post-DNA damage did not induce a significant DDR response
(Figure 35 A-C, 36A-L).
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Figure 34. Exosomes from undamaged cells do not increase activation of DDR
in recipient cells.
(A) Dose response of HPDE recipient cells treated with Panc1 naïve cell exosomes,
shown as % p-gH2AX positive cells. There was no significant increase in DDR
activation by exosomes from naïve cells, even with high exosome numbers. H2O2treated HPDE cells were used as a positive control. (B-D) Identical experimental
design was used to test exosomes from T3M4 (B), HPNE (C) and BJ cells (D),
respectively.
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Figure 35 DDR activation experiments done with Panc1 recipient cells.
(A) The same experimental strategies for HPDE recipient cells were employed.
Consistent with the previous data, exosomes from damaged cancer cells are able to
induce DDR in recipient cells. This panel shows the effect of exosomes isolated from
Panc1 cells treated with H2O2. Interestingly, this also demonstrates that exosomes
can induce DDR in cells that are the same type as their cell of origin. (B) Same
approach as in A, but with T3M4 exosomes and UV as the damaging agent. (C) As
demonstrated previously, exosomes from undamaged cells still could not generate
DDR in recipient cells. Shown are Panc1 cells incubated with exosomes from
untreated BJ fibroblasts in increasing concentrations. No significant induction of DDR
was observed. Scale bar 20µm.
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Figure 36. Panc1 recipient cells behave similarly to HPDE recipient cells.
(A) Panc1 recipient cells treated with H2O2-treated Panc1 exosomes (B) Panc1
recipient cells treated with H2O2-T3M4 exosomes. (C) Panc-1 recipient cells treated
with H2O2-treated HPNE exosomes (D) Panc1 recipient cells treated with H2O2-treated
BJ exosomes. (E) Panc1 recipient cells treated with UV-treated Panc1 exosomes. (F)
Panc1 recipient cells treated with UV-treated T3M4 exosomes. (G) Panc1 recipient
cells treated with UV-treated HPNE exosomes. (H) Panc1 recipient cells treated with
UV-treated BJ exosomes.

(I) Panc1 recipient cells treated with naive Panc1

exosomes. (J) Panc1 recipient cells treated with naive T3M4 exosomes. (K) Panc1
recipient cells treated with naive HPNE exosomes. (L) Panc1 recipient cells treated
with naive BJ exosomes.
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Exosome Treatment Does Not Damage the DNA of Recipient Cells
Next, we wanted to determine whether exosomes were somehow causing DNA
breaks in the recipient cells, in an effort to determine whether the activated DDR was
a result of physical DNA damage in the recipient cells or whether the activation
occurred by some other mechanism. To indirectly assess double stranded DNA
breaks (DSBs) we performed staining for the DNA repair protein RAD51, which
localizes to the physical sites of DNA damage325. Thus, in the case of increased DNA
damage by exosomes, we expected increased levels of RAD51 in the nuclei of
exosome-treated recipient cells. However, we did not observe nuclear RAD51
upregulation in any of the exosome-treated conditions (Figure 37). This result implies
that recipient cell DNA is not being damaged by exosome treatment, however a major
caveat is that RAD51 is involved in homologous repair, and is thus only detectable in
S-phase cells. In order to clearly assess the integrity of the recipient cell DNA,
additional experiments must be performed, such as Comet assays to assess
fragmentation and identify single vs double strand DNA species.
Exosomes From Damaged Cancer Cells Contain Activated DDR Pathway Proteins
To further investigate the potential mechanism by which exosomes from cells
undergoing DNA damage propagate DDR, we proceeded to analyze exosome cargo.
Since we observed that the exosome DNA content in most cases did not significantly
change, it is unlikely that exosome DNA mediates the DDR transmission by
exosomes, as was initially hypothesized. We therefore chose to examine exosome
protein content, specifically proteins involved in the activation and propagation of
DDR.
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Figure 37. Exosomes do not cause DNA damage in recipient cells.
HPDE recipient cells were incubated with Panc1 exosomes isolated from either naive,
H2O2, or UV-treated cells. None of these generated an increase in RAD51 expression
in recipient cells, suggesting no induction of DNA damage.

There are several proteins involved in the sensing of DNA damage, as well as
subsequent downstream activation of DDR mediators and effectors that dictate cell
fate outcomes. We posited that, potentially, exosomes might be transferring activated
DDR pathway proteins to recipient cells, allowing for horizontal activation in the
recipient cells. We focused specifically on the proteins CHK1 and CHK2 downstream
of the apical kinases ATR and ATM, respectively, in the DNA damage response
pathway325.
CHK1 and CHK2 are 56 and 62 kDa proteins that could be easily packaged
into exosomes. In the canonical DDR pathway, CHK1 and CHK2 are phosphorylated
by ATR/ATM and recruit downstream effectors such as p53 and CDC25325. We
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generated protein lysates from three cell lines (Panc1, T3M4, HPNE) under 3 different
conditions (naïve, H2O2-treated, UV-treated), and performed Western blots for
phosphorylated CHK2. Phospho-CHK2 was indeed present and upregulated in cells
when DNA damage was induced (Figure 38A). Next, we probed for p-CHK2 in protein
extracts from exosomes from the same cells, identically treated. We observed that,
highly consistent with the results of p-gH2AX staining, p-CHK2 was increased in the
exosomes isolated from cells that underwent DNA damage, and was much higher in
the exosomes from cancer cells compared to exosomes from non-malignant cells
exposed to the DNA damaging agents (Figure 38B). Finally, we probed for p-CHK1,
with similar results. Interestingly, however, p-CHK1 levels were relatively high in
exosomes from naïve cancer cells (Figure 38C).
Conclusion
This exciting data is the first reported evidence that exosomes carry activated
DNA damage response proteins that could possibly have functional outcomes in
recipient cells. While further analysis is required to better establish and characterize
the shuttling of these proteins to recipient cells via exosomes, this is promising
evidence of a potential mechanism of exosome-mediated paracrine DDR activation.
A schematic of the proposed mechanism is shown in Figure 39. Interestingly, only
exosomes from damaged malignant cells were able to induce DDR in recipient cells,
which could be due to survival adaptations that are tumor specific. While further
investigation is required to elucidate the exact mechanisms of exosome-mediated
DDR activation, this data provides evidence that exosomes are important signaling
vehicles in the tumor microenvironment.
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Figure 38. Western Blots for p-CHK1 and p-CHK2 show the presence of
activated DDR proteins in cancer cell exosomes with induced DNA damage.
(A) Protein lysates from Panc1, T3M4, and HPNE cell lines untreated, H2O2 treated,
or UV treated were indicated were run on polyacrylamide gels, transferred to PVDF
membranes and proved with antibodies for phospho-CHK2. Phosphorylated CHK2 is
present in cells and is upregulated upon DNA damage induction, as expected. (B) Blot
for p-CHK2 using protein lysates isolated from the same cells treated with indicated
agents, as in A. Phosphorylated CHK2 is present in exosomes and increased in those
isolated from cancer cells undergoing DNA damage. (C) Blot for p-CHK1 using the
same exosome lysates as in B. Phosphorylated CHK1 is also present in exosomes
and increased in those isolated from damaged cancer cells. Interestingly, p-CHK1 was
also highly expressed in undamaged cancer cell exosomes.

Figure 39. Working Model of Exosome DDR Activation.
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CHAPTER 7
DISCUSSION AND FUTURE DIRECTIONS
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Discussion
Characterization of Exosomal DNA
Exosomes have been repeatedly demonstrated to have heterogeneous
functions and cargo, implying potential roles for them in a variety of biological
contexts202. While many of the molecules found in exosomes, such as proteins and
RNA, have been extensively investigated, exosomal DNA has remained largely
unexplored. Here, we sought to provide better characterization of exosomal DNA and
establish groundwork for further study.
The canonical definition of exosomes is that they are heterogeneous vesicles
surrounded by lipid bilayer, between 50-150nm in size, released from multi-vesicular
bodies into the extracellular milieu, and eventually make their way into body fluids
including blood, urine, saliva, etc40. True to the definition of heterogeneity, exosomes
are broadly varied in terms of their DNA content, depending on their cell line of origin.
Through the isolation of exosomal DNA from a large number of cell lines spanning a
wide variety of malignant and non-malignant cell types, we were able to show that the
amount of DNA packaged into exosomes changes on a cell-by-cell basis. This is an
important consideration for the potential development of diagnostic tools based on
exosomal DNA, as their potential utility would depend on how much DNA the cells
/tissues of interest, such as tumors, package into their exosomes.
Evaluation of Exosome Isolation Methods for DNA Collection
Among the most controversial topics in the exosome field is identifying the best
method of exosome isolation. As exosomes have grown in popularity in the research
community, numerous isolation technologies, from affinity columns to precipitation
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reagents, have been developed. Each method has distinct advantages and
drawbacks, and ultimately the best technique likely depends on the desired
downstream application. In the context of exosomal DNA, a recent study by Jeppesen
et al218 utilized the method of ultracentrifugation in a buoyancy flotation iodixanol
gradient (IG), yielding high purity exosome populations based on particle size and
surface markers. However, these particles were devoid of DNA. We chose to
investigate this method, as well as the two other most commonly used isolation
techniques, size exclusion chromatography (SEC) and ultracentrifugation (UC), to
provide a comprehensive evaluation of exosomal DNA and the effects of different
isolation methods on the DNA yields and quality. We were able to definitively prove
the presence of double-stranded DNA content associated with exosomes isolated by
each method, including IG. Additionally, we utilized DNase I treatment prior to
exosome lysis to demonstrate that intravesicular DNA content is protected from
DNase digestion by the lipid bilayer. Therefore, the DNase resistant DNA associated
with exosomes is localized inside the exosome lumen. We employed multiple forms
of characterization, including flow cytometry, western blotting for established exosome
markers, and nanoparticle tracking analysis (NTA) to demonstrate the purity, integrity
and identity of the exosomes.
Overall, while we showed that exosomal DNA is present in exosomes isolated
by each method, not every method is was equally efficient in terms of the quality and
quantity of exosomal DNA extracted. UC generated the largest amount of total DNA,
however it was most susceptible to DNase treatment, showing that much of the DNA
in UC exosome preparations is extravesicular. There were also other contaminants
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present, such as cell-free DNA and protein. This is to be expected, as UC isolation is
based on sedimentation by centrifugation forces and precipitates all material in a given
sample. The optiPrep density gradient is designed to separate subfractions of
exosomes by size, and indeed with the high number of ultracentrifugation washes
involved this method yielded relatively pure populations. However, due to the multiple
wash steps, the yields were surprisingly low, despite high input (number of flasks/cells
used for exosome harvest). The quality of the DNA, as ascertained by chip
electrophoresis, was generally much lower as well. It has been shown that high-speed
ultracentrifugation can be damaging to exosome membranes235, and while the
optiPrep itself may be a gentle mode of isolation, the four wash steps could serve to
rupture and degrade exosomes and their contents, making this method less than ideal
in terms of the yields of exosomes and luminal cargo for further applications. The best
method for the isolation of exosomal DNA, at least among those tested by us, was
size exclusion chromatography. Known to be a kinder method of obtaining exosomes,
as it uses the force of gravity to pass samples through a gel-filtration resin, we saw
the highest yields with the least susceptibility to DNase treatment. This coupled with
the ease of isolation and minimal exosome loss pointed to SEC as the superior
technique for collecting exosomal DNA.
Exosomal DNA is Methylated
Only two groups have previously shown the presence of methylation marks on
exosomal DNA47,289. Additionally, neither went into much depth in terms of
characterizing the scale of exosomal DNA methylation or testing whether exosome
methylation patterns could readily and reproducibly provide insight into the epigenome
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of the cells of origin, such as pro-tumorigenic methylation states. Here, we
demonstrated conclusively that exosomal DNA is, in fact, methylated. We were able
to successfully perform reduced representation bisulfite sequencing and characterize
the methylome of both tumorigenic and non-tumorigenic human pancreatic cells.
Furthermore, with only ~200ng of input DNA, we were able to evaluate each sample
on an individual base-pair level. This allowed an investigation into site-specific
promoter methylation patterns, which led us to identify matched differentially
methylated sites in the exosomal and nuclear DNA from tumorigenic vs. nontumorigenic cells. This opens up the potential opportunity to utilize exosomal DNA
methylation patterns as a complement to conventional mutation analysis for cancer
diagnostics and monitoring. Since exosomes are readily isolated in the bodily fluids of
patients, exosomal DNA mutations and methylation patterns could be utilized as a
viable non-invasive method for liquid biopsy.
Exosomal DNA Methylation Patterns Are Cell Line Specific
Using correlation analyses, we compared the methylation patterns obtained
from exosomes isolated from different cell lines. Remarkably, the exosomal DNA not
only almost fully recapitulated the methylation patterns of the cells of origin, but it could
also be used to directly identify the cells of origin. Therefore, we indicate for the first
time that exosomal DNA carries a distinct, cell-specific signature that can be readily
detected for analysis and evaluation. This characteristic could prove invaluable for the
early detection of diseases like cancer, which are often asymptomatic and difficult to
detect in early stages. In preliminary work, we isolated DNA from matched tumor
tissue and serum exosomes from PDAC patients for initial evaluation of the clinical
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utility of exosomal DNA methylation for tumor detection. Thus far, we have been able
to successfully perform whole genome methylation sequencing of the serum exosome
DNA, and sequence analysis is ongoing.
Exosome DNA Packaging
To date, there is no established mechanism for the packaging of DNA into
exosomes. While several studies have suggested that factors such as increased DNA
damage and fragmentation, as well as the genomic instability inherent to diseases
such as cancer, could lead to more DNA becoming available to be sorted into
exosomes276, no work has been done to specifically identify how DNA could escape
the nucleus into the cytosol for subsequent incorporation into exosomes for
extracellular release. Here, our initial findings indicate the potential importance of
nuclear membrane integrity for the loading of exosomes into DNA. Upon successful
knockdown of Lamins A and C, two major structural components of nuclear envelope,
we observed a significant increase in exosomal DNA in three cell lines with different
phenotypes.
Thus, while further investigation is still needed, we propose that the disruption
of nuclear envelope is a critical part of the mechanism of DNA transfer from the
nucleus to multi-vesicular bodies. One of the major unanswered questions regarding
DNA packaging into exosomes is how exosome DNA, cumulatively, can span the
whole genome with no apparent biases. If nuclear envelope integrity is in fact critical
for exosomal DNA packaging, then the nuclear breakdown during cell cycle
progression may be the next critical area of investigation regarding the mechanism of
DNA packaging into exosomes. An interesting potential experiment would involve cell
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cycle arrest to synchronize cells, releasing them into S phase, and then damaging the
DNA in a site-specific manner, using an agent such as cisplatin, to observe whether
a parallel increase in site-specific DNA fragments are found in exosomes isolated from
those cells. This would provide crucial information regarding the mechanism of
exosomal DNA packaging and its potential relationship to nuclear envelope integrity,
cell cycle progression, and DNA damage. Understanding the mechanism of exosomal
DNA packaging would provide critical insight that could be used to identify the best
contexts in which exosomal DNA would have the highest diagnostic or prognostic
utility, perhaps in some pathological or stress-induced states that would produce more
DNA for isolation and analysis. Here, we provide a first step towards elucidating the
mechanism of exosomal DNA packaging.
Exosomes as DNA Damage Response Mediators
For many years, studies have shown that radiation treatment can induce
bystander DNA damage responses (DDR) in treatment naïve cells309. While some
molecular mediators, such as ROS326, have been implicated in these effects, the
molecular mechanisms of bystander responses remain unclear. Here, we
demonstrate that exosomes from cancer cells with induced DNA damage can activate
DDR in treatment-naïve cells, thus serving to propagate cellular stress signals. It has
been shown that several tumor types can influence the microenvironment with protumorigenic secretory signaling in times of cytotoxic stress327. We identify exosomes
as a vehicle of intercellular communication, to transfer DNA damage stress responses
between cancer cells and both malignant and non-malignant cells in the tumor
microenvironment. Potentially, exosome-transmitted DDR can also be communicated
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to peripheral organs, including myeloid cells of immune system, causing the formation
of pre-metastatic niches or inducing pro-tumorigenic pathways. Indeed, it has been
shown that genotoxic cancer treatments can activate DDR programs in naïve cells,
leading to the generation of a pro-angiogenic, pro-inflammatory environments that are
tumor permissive328. Thus, exosome-assisted transmission of DDR could cause
enhanced treatment resistance, tumor growth, and metastasis. Identifying the
mechanisms by which exosomes mediate DDR activation could provide opportunities
for interventions to increase treatment efficacy, such as inhibiting exosome release
during chemotherapy or radiation.
Interestingly, non-malignant cells and undamaged cancer cells (not exposed to
DNA damaging agents) were incapable of DDR initiation in naïve cells, suggesting
that exosomes only acquire DDR-inducing cargo in cancer and DDR-specific contexts.
One potential mechanism that we have begun to investigate is the presence of
replication fork-protection defects in cancer cells that could lead to tumor-specific
responses to DNA damage. This work was initiated in collaboration with
Venkateswarlu Popuri, when we observed that only exosomes I generated from
tumorigenic cell lines, not non-tumorigenic lines, could elicit DDR signaling in naïve
cells. Additionally, non-tumorigenic cells may be more resistant to exosome uptake,
which could also explain the lack of increased DDR activation in those cells,
necessitating experiments with labeled exosomes to visualize whether exosomes
preferentially localize within malignant cells. This evidence supports the hypothesis
that cancer cells can utilize exosomes as a survival mechanism to enable treatment
resistance by evading DNA damage related death or senescence.
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Exosomes Carry Activated DNA Damage Response Pathway Proteins
While our group and others generated data that implicate exosomes in
bystander DDR activation320,329, the mechanisms by which exosomes mediate these
effects remain unknown. Here, we show for the first time that exosomes from cancer
cells with induced DNA damage contain activated (phosphorylated) DDR pathway
proteins, specifically CHK1 and CHK2. Up to this point, no other groups had observed
the paracrine transfer of activated DDR proteins, which could potentially induce
horizontal activation of the DDR cascade upon delivery to recipient cells. While this
initial data is promising, additional experimental validation of these results is required,
such as an assessment of total protein in comparison to phosphorylated protein alone,
as well as densitometry measurements for more accurate quantification. Additionally,
the levels of both total and phosphorylated protein need to be assessed in the recipient
cells, to demonstrate the functional transfer of these proteins. Further clarification of
the role of exosomes, specifically their cargo, in mediating DDR-inducing cancer cell
signaling could help clarify their roles in tumor-promoting programs such as treatment
resistance, enhanced growth, and survival. Manipulating exosome release or cargo
sorting could negatively impact tumor-promoting responses in the microenvironment
after genotoxic treatment, thus mitigating their protective effects and enhancing
treatment efficacy.
Future Directions
The future indications for this work involve further investigation into molecular
mechanisms of exosomal DNA packaging, exosome-transmitted DNA damage
response, and clinical applications of exosomal DNA as a biomarker source. My
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preliminary results suggest that exosomes could be used to assess the epigenetic
status of patient tumors and thus identify additional therapeutic targets and predict
treatment responsiveness. The primary short-term goal will be to continue to optimize
exosome isolation and DNA extraction from patient samples, including serum and
potentially other biofluids such as urine, to maximize DNA yield and quality for
downstream analyses, like sequencing or methylation sequencing, for both genomic
and epigenomic alterations. Subsequently, the development of a predictive biomarker
assay for tumor types that are difficult to detect early, such as PDAC, could allow for
patient-derived exosomal DNA sequencing data to inform early diagnostic capabilities.
Further work is also required for elucidating the detailed molecular and
biological mechanisms of exosome-mediated DDR activation. We would like to
investigate the cancer-specific nature of exosome-mediated DDR induction by utilizing
isogenic cell lines transformed with different oncogenes, such as Kras, to better
characterize the DDR induction capabilities of exosomes from transformed vs nontransformed cells. By performing a more detailed analysis of DDR pathway-related
exosome cargo and identifying how cancer cells can co-opt exosomes for stress
response signaling, potential targets for therapeutic intervention could be discovered.
Work could include an assessment of the effects of inhibiting exosome release on
DDR activation in naïve cells, or investigating whether cells with exosome-induced
DDR become more resistant to therapy or death signaling. Much remains to be
discovered regarding the roles of exosomes in patient treatment responses.
Exosome biogenesis and function is still a nascent field of study, where
relatively little is known regarding their physiological and pathological roles. Based on
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recent work demonstrating the transfer of functional molecules, including DNA, to
target cells via exosomes, there is considerable reason to believe that exosomes
could mediate an even broader range of paracrine effects. Exosomes travel easily
throughout the body and are released and taken up by all cell types, enabling their
potential involvement in a variety of functions, including DNA damage response
activation. Therefore, the future goals of this research will be to explore a potential
role for exosomes in improving diagnostic capacities, as well as investigating their
involvement in drug induced chemoresistance and tumor progression, all major
barriers for current cancer treatment efficacy. This research provides the foundation
for the advancement of therapeutic modalities using exosomes, as they can be easily
detected, targeted, and manipulated.
Conclusion
The main goal of this body of work was to gain more information about the
origin, function, and utility of exosomal DNA. As I hope I have conveyed, exosomal
DNA is packaged into exosomes in a cell type-specific manner and released into the
extracellular environment, where it can subsequently be transferred to recipient cells
or isolated for analysis. Exosome DNA has tremendous potential for therapy, both in
cancer and other diseases, as a diagnostic and monitoring tool. As more information
about exosomes is discovered, I believe that it is likely they will become important
factors in many therapies and detection assays. It is a privilege to contribute my work
to such an exciting and translationally relevant field of biology.
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